



2021 PAN PACIFIC LYMPHOMA CONFERENCE

August 9-13 / Fairmont Orchid / Big Island, Hawaii

CONFERENCE PROGRAM



University of Nebraska
Medical Center

Nebraska Medicine


Connect with us on  and  using #PPLC21 #IamUNMC

Download the event app



Stay up-to-date on PPLC 2021 by downloading the FREE event app!

1. Search for the “**eventScribe**” app in the Apple App Store or in Google Play or scan the QR code below.
2. Search for “**2021 PPLC**” inside the eventScribe App.
3. Login to create an account and use “**Hawaii21**” as the event code.



Laptop and other mobile device users, go to
<https://tinyurl.com/unmc2021>

We gratefully acknowledge the following for support of this conference:

PLATINUM SUPPORTER

Incyte Corporation

GOLD SUPPORTERS

AstraZeneca Pharmaceuticals
BeiGene
Pharmacyclics LLC, an AbbVie Company,
and Janssen Biotech Inc., administered by
Janssen Scientific Affairs LLC

SILVER SUPPORTERS

Genentech, a member of the Roche Group
MorphoSys US Inc.
Seagen, Inc.
Takeda Pharmaceuticals USA Inc.

BRONZE SUPPORTERS

ADC Therapeutics America, Inc.
GlaxoSmithKline
Sanofi Genzyme

COPPER SUPPORTERS

AbbVie Inc.
Acrotech Biopharma LLC
Adaptive Biotechnologies
Bristol-Myers Squibb
Epizyme, Inc.
Gamida Cell Inc.
Genmab
Karyopharm Therapeutics Inc.
Kite Pharma, Inc.
Novartis
Oncopeptides
TG Therapeutics Inc.

SUPPORTER

Verastem Oncology

EDUCATIONAL GRANTS

AbbVie Inc.
ADC Therapeutics America, Inc.
AstraZeneca Pharmaceuticals
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Incyte Corporation
Gilead Sciences, Inc.
Kite Pharma, Inc.
Seattle Genetics Inc.



WELCOME

Welcome to the 2021 Pan Pacific Lymphoma Conference!

Since its inception in 1994, PPLC has grown and become a premier international conference on the latest advances in lymphoma. This year, we have decided to host a hybrid conference with an in-person activity at the Fairmont Orchid, Hawaii and a virtual option for attendees who are not able to travel. We are very happy to welcome over 550 attendees!

For your easy reference and convenience, we encourage you to download the conference mobile app or visit tinyurl.com/unmc2021. Please note that all references to conference days and times follow Hawaii Standard Time (HST).

Here's what you can expect for the week:

- **Day 1 (Monday):** We will feature an Interprofessional Education Day, with various presentations for the interprofessional lymphoma team members.
- **Days 2-5 (Tuesday through Friday):** Expert faculty will present in scientific sessions covering What's Next in Lymphoma, Moving CAR-T Forward, Ongoing Debates in Lymphoma, Best Management Strategies. Loretta J. Nastoupil, MD will present the James O. Armitage Lymphoma Clinical Investigator Award Lecture and Ranjana H. Advani, MD will deliver the Oliver Press Memorial Lecture, "Historical Development of Hodgkin Therapy at Stanford," in memory of our esteemed colleague, Oliver W. Press, MD, PhD.
- **Days 2-4 (Tuesday through Thursday) afternoons:** Join us for the Ask the Experts sessions where we will discuss iNHL, HGBCL, cHL, PTCL and MM. Also, on Day 2/Tuesday, we will have our fast-paced Lymphoma Jeopardy with four teams competing for Day 3/Wednesday's Pineapple Cup Lymphoma Jeopardy Finals.
- **Days 1-5 (Monday through Friday):** If you are joining us in-person, please come visit the exhibits in the Plaza Ballroom.
- **Days 1-4 (Monday through Thursday):** Please make time to join the industry-supported satellite symposiums. If you haven't registered to attend these, you may do so online. Note that AMA and ANCC credits are available for these symposiums held in conjunction with PPLC21.
- **Days 1-5 (Monday through Friday):** The conference e-poster gallery detailing the latest research in lymphoma and transplantation are also available via the conference mobile app and online.
- **Day 2 (Tuesday) evening:** If you are attending in-person, please join us for the Welcome Reception from 7-9 pm at the Croquet Lawn where you can meet and network with other conference attendees. Light hors d'oeuvres and beverages will be served. Paid/registered guests are welcome to attend.
- **Day 4 (Thursday) evening:** In-person attendees are encouraged to join the Conference Dinner from 7-9 pm at the Turtle Pointe. Dinner and beverages will be served while we enjoy a live band performance. Paid/registered guests are welcome to attend.

Friendly reminders if you are attending in-person:

- Please be sure that you and your paid guests wear your conference badge at all times.
- The attire for this conference is casual; layered clothing is recommended as temperature in meeting rooms can fluctuate. A light jacket or sweater for outdoor evening activities is suggested. Leave your ties in your room!

If you are on Twitter or Instagram, we encourage you to tag your photos and posts **#PPLC21** and **#IamUNMC**.

Once again, thank you for joining the 2021 Pan Pacific Lymphoma Conference. **Aloha!**

Conference Directors



James O. Armitage, MD

Joe Shapiro Professor of Medicine
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center



Matthew A. Lunning, DO, FACP

Associate Professor
Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center



Robbe L. Peetz, MBA, PA-C

Advanced Practice Provider Manager
Cancer Services
Nebraska Medicine



Tawny J. Roeder, RN, BSN, BMTCN

Case Manager
Blood and Marrow Transplantation
Division of Oncology and Hematology
Department of Internal Medicine
Nebraska Medicine



Julie M. Vose, MD, MBA

Neumann M. and Mildred E. Harris Professor
Chief, Division of Oncology and Hematology
Department of Internal Medicine
University of Nebraska Medical Center

CONFERENCE INFORMATION

Conference Registration Information

The Conference Registration and Information Desk is located in the Grande Ballroom Foyer on the Lobby Level of the Fairmont Orchid, Hawaii. Attendees may pick up their conference materials and name badges at this location. The Registration/Information Desk is open during the following times:

Sunday, August 8	2:00 p.m. - 4:00 p.m.
Monday, August 9	7:00 a.m. - 4:00 p.m.
Tuesday, August 10	7:00 a.m. - 12:00 p.m.
Wednesday, August 11	7:00 a.m. - 12:00 p.m.
Thursday, August 12	7:00 a.m. - 12:00 p.m.
Friday, August 13	7:00 a.m. - 12:00 p.m.

Mobile Device Use

We encourage you to use your mobile device to download the 2021 PPLC event app so you can have access to the entire conference program. Please remember to turn your mobile device to silent or vibrate mode when attending sessions.

Poster and Exhibit Hours

Monday, August 9	7:00 a.m. - 12:00 p.m.
Tuesday, August 10	7:00 a.m. - 12:00 p.m.
Wednesday, August 11	7:00 a.m. - 12:00 p.m.
Thursday, August 12	7:00 a.m. - 12:00 p.m.
Friday, August 13	7:00 a.m. - 10:00 a.m.

Internet Access



Complimentary WiFi is available in the conference area.
Network: UNMCPPLC21
Password: PPLC2021

Complimentary in-room WiFi is available for guests of the Fairmont Orchid, Hawaii.

Photography and Audio Visual Recording Policy

Please be aware that during the 2021 Pan Pacific Lymphoma Conference, attendees, vendors, guests, and exhibitors may be photographed or videotaped by UNMC and/or third parties authorized by UNMC. Some of these photographs or videos may be displayed by UNMC in future publications or other materials. By virtue of your attendance, you agree to allow UNMC to use photographs of you in these promotional materials.

Photographs taken for the purpose of sharing on social media are allowed, but should avoid showing presentation slides. Please use #PPLC21 when posting on social media.

Children and Other Accompanying Guests

PPLC 2021 does not offer childcare services. Due to limited seating capacity and the highly technical nature of the program, children are not allowed to attend sessions. For their safety, children must be accompanied by an adult at all times during the conference.

Registered accompanying guests may join conference registrants at the following food functions:

- Continental breakfasts (7-9 a.m.) and breaks as part of the main conference from Monday through Friday
- Welcome Reception on Tuesday evening
- Conference Dinner on Thursday evening


Name badges will be required at these conference food functions.

Venue Floor Plan



Session and Room Assignments

- F GRANDE BALLROOM FOYER**
Conference Registration
- G GRANDE BALLROOM**
Scientific Sessions
Lymphoma Jeopardy
Ask the Experts
Satellite Symposiums
- P PLAZA BALLROOM**
Continental Breakfast
Exhibits
Refreshment Breaks
- CROQUET LAWN**
Welcome Reception — Tuesday, August 10 from 7-9 p.m.
- TURTLE POINTE**
Conference Dinner — Thursday, August 12 from 7-9 p.m.



EDUCATION INFORMATION

Target Audience

The 2021 Pan Pacific Lymphoma Conference is one of the largest gatherings of clinicians and researchers specializing in the areas of lymphoma and transplantation. The 2021 conference will benefit members of the multidisciplinary lymphoma clinical team including oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists.

Conference Objectives

At the conclusion of the conference, the participant should be better able to:

1. Discuss patient and disease-related factors that impact the diagnosis, prognosis, and approaches to treatment of hematologic malignancies, including lymphoma, myeloma, leukemia
2. Assess clinical trial data of current and emerging agents and regimens that impact management strategies for patients with Non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL)
3. Describe currently available and novel investigational strategies for the treatment and maintenance of patients with multiple myeloma (MM)
4. Evaluate results of clinical trials investigating treatment approaches for patients with acute and chronic leukemias
5. Develop strategies to integrate emerging therapeutic strategies into the armamentarium for patients with hematologic malignancies
6. Identify factors that improve patient quality-of-life including appropriate patient counseling and mitigating treatment-related adverse events
7. Analyze factors that impact enrollment of patients with lymphoma, leukemia and myeloma into clinical trials examining novel treatment approaches
8. Explain the roles of the interprofessional health care team in the diagnosis, treatment, management and support of lymphoma and hematologic malignancies

Disclosure Declaration

As a jointly accredited provider, the University of Nebraska Medical Center (UNMC) ensures accuracy, balance, objectivity, independence, and scientific rigor in its educational activities and is committed to protecting learners from promotion, marketing, and commercial bias. Faculty (authors, presenters, speakers) are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or other options available when utilizing trade names to ensure impartiality.

All faculty, planners, and others in a position to control continuing education content participating in a UNMC accredited activity are required to disclose all financial relationships with ineligible companies. As defined by the Standards for Integrity and Independence in Accredited Continuing Education, ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. The accredited provider is responsible for mitigating relevant financial relationships in accredited continuing education. Disclosure of these commitments and/or relationships is included in these activity materials so that participants may formulate their own judgments in interpreting its content and evaluating its recommendations.

This activity may include presentations in which faculty may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.

All materials are included with the permission of the faculty. The opinions expressed are those of the faculty and are not to be construed as those of UNMC.

The accredited provider has mitigated and is disclosing identified relevant financial relationships for the following faculty, planners, and others in control of content prior to assuming their roles:

FACULTY

Jeremy S. Abramson, MD, MMSc

CONSULTANT: AbbVie; Allogene; AstraZeneca; BeiGene; Bluebird Bio; C4 Therapeutics; Celgene; EMD Serono; Genentech; Incyte; Karyopharm; Kite Pharma; Kymera; MorphoSys

Ranjana H. Advani, MD

CONSULTANT: ADC Therapeutics; BeiGene; Daiichi Sankyo; Incyte Corp.; Karyopharm; Kura; Portola Pharmaceuticals; Sanofi
RESEARCH FUNDING: Bristol Myers Squibb; Celgene; Kura; Merck; Roche/Genentech; Seattle Genetics; Takeda/Millennium
ADVISORY BOARD: Roche/Genentech
HONORARIUM: Roche/Genentech

Stephen M. Ansell, MD, PhD

GRANT/RESEARCH SUPPORT: ADC Therapeutics; Bristol Myers Squibb; Regeneron; Seattle Genetics; Trillium
RESEARCH FUNDING: Bristol Myers Squibb; Regeneron; Seattle Genetics; Trillium

James O. Armitage, MD

CONSULTANT: Ascentage; Samus Therapeutics
MEMBER, BOARD OF DIRECTORS: Cardiff Oncology

Muhamed Baljevic, MD, FACP

ADVISORY BOARD: Bristol Myers Squibb; Janssen Biotech; Oncopeptides
CONSULTANT: Bristol Myers Squibb
IRC MEMBER FOR PHASE 3 BOSTON: Karyopharm

Sally F. Barrington, MBBS, MSc, FRCP, FRCR, MD

DEPARTMENTAL RESEARCH FUNDING: Amgen Inc.; Bristol Myers Squibb; Pfizer
SPEAKERS BUREAU: Takeda/Millennium

Nancy L. Bartlett, MD

ADVISORY BOARD: ADC Therapeutics; Genentech/Roche; Seattle Genetics, Inc.
GRANT/RESEARCH SUPPORT: ADC Therapeutics; Celgene; Genentech/Roche; Janssen; Merck; Millennium; Pharmacyclics
RESEARCH FUNDING: ADC Therapeutics; Autolus; Bristol Myers Squibb; Celgene; Forty Seven, Inc.; Genentech/Roche; Janssen; Kite Pharma; Merck; Millennium; Pharmacyclics; Seattle Genetics, Inc.

R. Gregory Bociek, MD, MSc, FRCP(C)

CONSULTANT: Innate Pharma
DATA SAFETY MONITORING BOARD: Innate Pharma

Reiner J. Brentjens, MD, PhD

ROYALTIES: Bristol Myers Squibb
CONSULTANT: Bristol Myers Squibb
SPEAKER: Bristol Myers Squibb
ADVISOR: Gracell Therapeutics

Carla Casulo, MD

RESEARCH FUNDS: Bristol Myers Squibb; Genentech; Gilead Sciences, Inc.; Verastem

Bruce D. Cheson, MD, FACP, FAAAS, FASCO

CONSULTANT: Beigene; Karyopharm; Merck Sharp & Dohme Corp.

Jonathon B. Cohen, MD, MS

ADVISOR: Adaptive Biotechnologies; Adicet; AstraZeneca; BeiGene; Janssen; Kite/Gilead; Loxo Oncology
ADVISORY BOARD: Adicet; AstraZeneca; BeiGene;
CONSULTANT: Janssen
RESEARCH FUNDING: Adicet; AstraZeneca; Bristol Myers Squibb/Celgene; Genentech; LAM; Loxo Oncology; Takeda
GRANT/RESEARCH SUPPORT: Bristol Myers Squibb/Celgene; Genentech; LAM; Loxo Oncology; Takeda

Alexey V. Danilov, MD, PhD

CONSULTANT: AbbVie; AstraZeneca; Bayer Healthcare Pharmaceuticals; BeiGene; Bristol-Meyers Squibb; Genentech; Janssen/Pharmacyclics; TG Therapeutics
RESEARCH FUNDING: AbbVie; AstraZeneca; Bayer Healthcare Pharmaceuticals; Bristol-Meyers Squibb; Epizyme; Genentech; SecuraBio; Takeda/Millennium; TG Therapeutics

Matthew S. Davids, MD, MMSc

CONSULTANT: AbbVie; Adaptive Biotechnologies; Ascentage Pharma; AstraZeneca; BeiGene
RESEARCH SUPPORT: AbbVie; Ascentage Pharma; AstraZeneca
ADVISORY BOARD: Ascentage Pharma; AstraZeneca
GRANT/RESEARCH SUPPORT: Ascentage Pharma; AstraZeneca

EDUCATION INFORMATION

Timothy S. Fenske, MD, MS

CONSULTANT: AbbVie; Adaptive Biotechnologies; Genentech; Karyopharm; Kite Pharma; MorphoSys; Pharmacyclics; Sanofi Genzyme; TG Therapeutics; Verastem

SPEAKER: Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; Bristol Myers Squibb; Genentech; Karyopharm; Kite Pharma; Sanofi Genzyme; Seattle Genetics; TG Therapeutics; Verastem

Richard I. Fisher, MD

CONSULTANT: Bayer

Christopher R. Flowers, MD, MS, FASCO

CONSULTANT: AbbVie; Bayer; BeiGene; Celgene Corporation; Denovo Biopharma; Genentech/Roche; Genmab A/S; Gilead Sciences, Inc.; Janssen/Pharmacyclics; Karyopharm; Pharmacyclics; Spectrum

RESEARCH FUNDING: AbbVie; Acerta; Adaptimmune; Allogene; Amgen Inc.; Bayer Healthcare Pharmaceuticals; Burroughs Wellcome Fund; Cancer Prevention and Research Institute of Texas: CPRIT Scholar in Cancer Research; Celgene; Cellectis; Eastern Cooperative Oncology Group; EMD Serono; Genentech/Roche; Gilead Sciences, Inc.; Guardant; Iovance; Janssen; Kite Pharma; MorphoSys; National Cancer Institute; Nektar; Novartis Pharmaceuticals; Pfizer; Pharmacyclics; Sanofi; Takeda/Millennium; TG Therapeutics; V Foundation; Xencar; Ziopharm

Jonathan W. Friedberg, MD, MMSc

DATA SAFETY MONITORING BOARD: Astellas

Tara M. Graff, DO, MS

SPEAKER - ADVISORY BOARD: AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene; Karyopharm; TG Therapeutics

Krishna Gundabolu, MBBS, FACP

ADVISORY BOARD: Biomarin; Blueprint Medicines; Bristol Myers Squibb; Jazz Pharmaceuticals; Novartis Pharmaceuticals; Pfizer

STOCKHOLDER: Geron

CLINICAL TRIAL PI: Samus Therapeutics

Keely M. Hack, MD

CONSULTANT: Denovo Biopharma; Genentech/Roche; Genmab A/S; Gilead Sciences, Inc.; Janssen/Pharmacyclics; Karyopharm; Pharmacyclics; Spectrum

RESEARCH FUNDING: Cellectis; Eastern Cooperative Oncology Group; EMD Serono; Genentech/Roche; Gilead Sciences, Inc.; Guardant; Iovance; Janssen; Kite Pharma; MorphoSys; National Cancer Institute; Nektar; Novartis Pharmaceuticals; Pfizer; Pharmacyclics; Sanofi; Takeda/Millennium; TG Therapeutics; V Foundation; Xencar; Ziopharm

Steven M. Horwitz, MD

CONSULTANT: Acrotech Biopharma; ADC Therapeutics; Astex; C4 Therapeutics; Celgene; Janssen Biotech; Kura Oncology; Kyowa Hakko Kirin Pharma; Myeloid Therapeutics; ONO Pharmaceuticals; Seattle Genetics; SecuraBio; Takeda/Millennium; Trillium Therapeutics; Verastem; Vividion Therapeutics

RESEARCH GRANT SUPPORT: ADC Therapeutics; Affimed; Aileron Therapeutics; Celgene; Daiichi Sankyo; Forty Seven, Inc.; Kyowa Hakko Kirin Pharma; SecuraBio; Takeda/Millennium; Trillium Therapeutics; Verastem

Brad S. Kahl, MD

CONSULTANT: AbbVie; ADC Therapeutics; AstraZeneca; Bayer; Beigene; Bristol Myers Squibb; Celgene; Genentech; Incyte; Janssen; Karyopharm; Kite; Pharmacyclics; Roche; Teva

John P. Leonard, MD

ADVISORY BOARD: Miltenyi Biotec

CONSULTANT: AbbVie; Bayer; Bristol Myers Squibb; Celgene; Genentech; Genmab A/S; Gilead; Incyte; Juno Therapeutics; Karyopharm; Miltenyi Biotec; Regeneron; Sutro

Matthew A. Lunning, DO, FACP[®]

CONSULTANT: Acrotech Biopharma; AstraZeneca/Acerta; Beigene; Bristol Myers Squibb; Celgene; Daiichi Sankyo; Gilead Sciences; Janssen/Pharmacyclics; Karyopharm; Kite; Legend Pharmaceuticals; MorphoSys; Myeloid Therapeutics; Spectrum; TG Therapeutics; Verastem

RESEARCH GRANT SUPPORT: Bristol-Myers Squibb; Curis

ADVISORY BOARD: Celgene

David G. Maloney, MD, PhD

ADVISORY BOARD: A2 Biotherapeutics; Amgen; Bristol Myers Squibb; Celgene Corporation; Genentech; Janssen; Juno Therapeutics; Kite Pharma; MorphoSys; Novartis; Pharmacyclics

STOCK OPTIONS: A2 Biotherapeutics

RESEARCH FUNDING: Celgene Corporation; Juno Therapeutics; Kite Pharma

PATENTS PENDING: Juno Therapeutics

David B. Miklos, MD, PhD

RESEARCHER: Adaptive Biotechnologies; Adicet; Allogene; Kite/Gilead; Miltenyi Biotec; Novartis

Alison J. Moskowitz, MD

RESEARCH SUPPORT: ADC Therapeutics; Bristol Myers Squibb; Incyte Corp.; Merck; Seattle Genetics

CONSULTANT: Imbrium Therapeutics L.P.; Janpix Ltd.; Merck miRagen; Seattle Genetics; Takeda/Millennium

Loretta J. Nastoupil, MD

HONORARIUM: ADC Therapeutics; Bayer; Celgene; Epizyme; Gilead; Janssen; Novartis; TG Therapeutics

ADVISORY BOARD: ADC Therapeutics; Bayer; Celgene; Epizyme; Gilead; Janssen; Novartis; TG Therapeutics

Grzegorz S. Nowakowski, MD

CONSULTANT: Bantam

Susan M. O'Brien, MD

RESEARCH SUPPORT: Acerta

CONSULTANT: Amgen

ADVISORY COMMITTEE/BOARD MEMBER: AstraZeneca

Tawny J. Roeder, RN, BSN, BMTCN

SPEAKERS BUREAU: Gilead

Kerry J. Savage, MD, MSc, FRCPC

CONSULTANT: Bristol Myers Squibb; Merck

HONORARIUM: Bristol Myers Squibb; Merck; Seattle Genetics

INSTITUTIONAL RESEARCH FUNDING: Roche/Genentech

ADVISORY BOARD: Seattle Genetics

Nina Shah, MD

RESEARCH FUNDING: Celgene; Janssen; Bluebird Bio; Sutro Biopharma; Teneobio

ADVISORY ROLE: Genentech; Surface Oncology; Precision Biosciences; GSK; Nektar; Amgen; Indapta Therapeutics; Sanofi; Bristol Myers Squibb

STOCK: Indapta Therapeutics

Sonali M. Smith, MD

GRANT/RESEARCH SUPPORT: Acerta; Celgene; Epizyme; Novartis; Pharmacyclics; Roche/Genentech; TG Therapeutics

ADVISORY BOARD: Bantam; Bristol Myers Squibb; Celgene; Janssen; Karyopharm; MorphoSys; Pharmacyclics

CONSULTANT: Bantam; Bristol Myers Squibb; Celgene; Janssen; MorphoSys

CLINICAL TRIALS: Acerta; Epizyme; Karyopharm; Pharmacyclics; Roche/Genentech; TG Therapeutics

Judith Trotman, MBChB, FRACP, FRCPA

CLINICAL TRIALS: Beigene; Celgene Corporation; Janssen/Pharmacyclics; Roche/Genentech

Julie M. Vose, MD, MBA

ADVISORY COMMITTEE/BOARD MEMBER/ADVISORY BOARD: AbbVie; Acerta/AstraZeneca; Pharmacyclics

CONSULTANT: MorphoSys

Luhua (Michael) Wang, MD

GRANT/RESEARCH SUPPORT: AstraZeneca; Janssen

CONSULTANT: AstraZeneca

Jason R. Westin, MD, MS, FACP

CONSULTANT: ADC Therapeutics; AstraZeneca; Bristol Myers Squibb; Genentech; Gilead Sciences; Iksuda; MorphoSys; Novartis; Umoja

CLINICAL RESEARCH FUNDING: AstraZeneca; Bristol Myers Squibb; Genentech; Gilead Sciences; MorphoSys; Novartis

Andrew D. Zelenetz, MD, PhD

CONSULTANT: AbbVie; Adaptive Biotechnology; Amgen; AstraZeneca; Celgene; Gilead; Janssen; Mei Pharma; MorphoSys; Novartis; Roche/Genentech

DMC CHAIR: BeiGene; Bristol Myers Squibb; Celgene; Juno

RESEARCH: Beigene; Gilead; Mei Pharma; Roche

Pier Luigi Zinzani, MD, PhD

HONORARIA/SPEAKER'S BUREAU: Astellas; Celltrion; Gilead; MSD

ADVISOR: Gilead; Kirin Kyowa; Verastem

OFF-LABEL, EXPERIMENTAL OR INVESTIGATIONAL USE OF DRUGS DISCLOSURE**R. Gregory Bociek, MD, MSc, FRCP(C)**

Clinical trials | Manufacturer: various | Off-label Use: Cytotoxics, monoclonal antibodies, targeted therapies

Bruce D. Cheson, MD, FACP, FAAAS, FASCO

Epcoritamab | Manufacturer: Genmab | Off-label Use: Lymphoma

Glofitamab | Manufacturer: Genentech | Off-label Use: Lymphoma

Magrolimab | Manufacturer: Gilead | Off-label Use: Lymphoma

Mosunetuzumab | Manufacturer: Roche-Genentech | Off-label Use: Lymphoma

Odrenextamab | Manufacturer: Regeneron | Off-label Use: Lymphoma

Matthew S. Davids, MD, MMSc

Venetoclax | Off-label Use: Management of NHL

Timothy S. Fenske, MD, MS

Breyanzi | Manufacturer: Bristol Myers Squibb | Off-label Use: Mantle cell lymphoma

Venetoclax | Manufacturer: AbbVie | Off-label Use: Mantle cell lymphoma

Christopher R. Flowers, MD, MS, FASCO

Bi-specific antibodies | Off-label Use: Experimental

Jonathan W. Friedberg, MD, MMSc

Novel agents for lymphoma | Off-label Use: unapproved

EDUCATION INFORMATION

Keely M. Hack, MD

Bi-specific antibodies | Off-label Use: Experimental

Steven M. Horwitz, MD

Checkpoint inhibitors for MF + SS

John P. Leonard, MD

Investigational Lymphoma Therapy | Manufacturer: Multiple | Off-label Use: Off-label Lymphoma Therapy

David G. Maloney, MD, PhD

CAR-T Cells | Manufacturer: Juno; Kite; Celgene

Alison J. Moskowitz, MD

Nivolumab | Manufacturer: Bristol Myers Squibb | Off-label Use: front-line use for Hodgkin lymphoma

Pembrolizumab | Manufacturer: Merck | Off-label Use: front-line use for Hodgkin lymphoma

Nina Shah, MD

CAR T cells | Manufacturer: Bristol Myers Squibb, Janssen | Off-label Use: myeloma

Sonali M. Smith, MD

I will be discussing the use of unlabeled/unapproved drugs or devices.

Luhua (Michael) Wang, MD

LOXO-305 | Manufacturer: Loxo | Off-label Use: Data

Jason R. Westin, MD, MS, FACP

Axi-cel | Manufacturer: Gilead | Off-label Use: 1.5L DLBCL

Ibrutinib | Manufacturer: Janssen | Off-label Use: 1L DLBCL

Lenalidomide | Manufacturer: Bristol Myers Squibb | Off-label Use: 1L DLBCL

Polatuzumab | Manufacturer: Genentech | Off-label Use: 1L DLBCL

Tafasitamab | Manufacturer: MorphoSys | Off-label Use: 1L DLBCL

Andrew D. Zelenetz, MD, PhD

ClonoSeq | Manufacturer: Adaptive Biotech | Off-label Use: offers reliable way to assess how disease burden changes

Pier Luigi Zinzani, MD, PhD

Bortezomib | Manufacturer: J&J | Off-label Use: off label

Copanlisib | Manufacturer: Bayer | Off-label Use: Investigational use

Duvelisib | Manufacturer: Verastem | Off-label Use: Investigational use

Idelalisib | Manufacturer: Gilead | Off-label Use: Investigational use

Lanalidomide | Manufacturer: Bristol Myers Squibb | Off-label Use: off label

Parsaclisib | Manufacturer: Incyte | Off-label Use: Investigational use

Umbralisib | Manufacturer: TG Therapeutics | Off-label Use: Investigational use

Zanubrutinib | Manufacturer: Beigene | Off-label Use: Investigational use

The following faculty members have nothing to disclose:

Catalina Amador, MD

Christopher D'Angelo, MD

Charles A. Enke, MD

Theresa Franco, MSN, RN

David S. Kroll, MD

Peihua (Peggy) Lu, MD

Jared E. Matya, PharmD, BCOP

Craig H. Moskowitz, MD

Robbe L. Peetz, MBA, PA-C

Christin A. Tiegs Heiden, MD

Meg Trehwhitt, APN-BC, AOCNP

PLANNING COMMITTEE

James O. Armitage, MD 

Matthew A. Lunning, DO, FACP 

Tawny J. Roeder, RN, BSN, BMTCN 

Julie M. Vose, MD, MBA 

The following planning committee members have nothing to disclose:

Jared E. Matya, PharmD, BCOP

Renee Paulin, MSN, RN, CWOCN

Robbe L. Peetz, MBA, PA-C

Brenda Ram, CMP, CHCP

Continuing Education Credits



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS

The University of Nebraska Medical Center designates this live activity for a maximum of 29.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES

The University of Nebraska Medical Center designates this activity for up to 29.25 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

PHARMACISTS



The University of Nebraska Medical Center designates this activity for 29.25 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 30 days after the activity completion.

Maintenance of Certification (MOC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 29.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

How to Claim Credit

PHYSICIANS CLAIMING MOC CREDIT:

To obtain credit, you must complete the evaluation in the app.

- On the front screen, select the Evaluation tile
- Update your profile information
- Complete the pretest for MOC credit
- Select the Scientific Sessions you attended and complete the evaluation for each session
- Complete the general conference evaluation
- Complete the post test for MOC credit
- Retrieve your certificate

NON-PHYSICIANS OR PHYSICIANS NOT CLAIMING MOC CREDIT:

To obtain credit, you must complete the evaluation in the app.

- On the front screen, select the Evaluation tile
- Update your profile information
- Select the Scientific Sessions you attended and complete the evaluation for each session
- Complete the general conference evaluation
- Retrieve your certificate

The deadline to claim continuing education credit for this conference is October 13, 2021.

CLAIMING PHARMACY CREDIT:

In order for pharmacists to claim credit for their participation in the conference, each individual must complete the evaluation in the conference app, and ensure that their date of birth (mm/dd), as well as their NABP ID # is on record with UNMC/CCE. Your NABP ID# is different than your license number.




Pharmacists have up to 30 days to complete the evaluation and claim credit for participation. UNMC CCE will supply the necessary information to CPE Monitor.

We will not be able to accept requests for ACPE credit after September 13, 2021.


CONFERENCE AGENDA

Monday, August 9

Interprofessional Education

- 7:00 a.m.** Conference Registration  / Breakfast 
- 7:45 a.m.** Welcome 
Matthew A. Lunning, DO, FACP and Tawny J. Roeder, RN, BSN, BMTCTN

SCIENTIFIC SESSIONS

- 8:00 a.m.** High Cost Services in Lymphoma
Theresa Franco, MSN, RN
- 8:40 a.m.** Involving Palliative Care in Lymphoma Management
Meg Trehwhitt, APN-BC, AOCNP
- 9:10 a.m.** Recognizing and Treating Depression and Anxiety in Lymphoma Patients
David S. Kroll, MD
- 9:40 a.m.** Supportive Therapies for Novel Oral Therapies
Jared E. Matya, PharmD, BCOP
- 10:10 a.m.** Break 
- 10:25 a.m.** Radiographic Images in Lymphoma
Christin A. Tiegs Heiden, MD
- 11:05 a.m.** Anticoagulation Management in Hematologic Malignancies
Krishna Gundabolu, MBBS, FACP
- 11:35 a.m.** Utilization of Advanced Practice Providers in Lymphoma: Roundtable
Robbe L. Peetz, MBA, PA-C
- 12:15 p.m.** Adjourn

SATELLITE SYMPOSIUMS

- 1:00-2:30 p.m.** Expert Second Opinion - Investigators Discuss How They and Their Colleagues Navigate Emerging Clinical Research and Challenging Cases of Acute Myeloid Leukemia and Myelodysplastic Syndromes
Administered by Research To Practice
Supported by Educational Grants from AbbVie, Inc. and Bristol-Myers Squibb Company and Takeda Oncology

 All times are displayed in Hawaii Standard Time (HST)

- 3:00-5:00 p.m.** Expert Tumor Board to Address Challenging Cases of Relapsed/Refractory Aggressive and Indolent Lymphomas
Administered by Bio Ascend
Supported by Educational Grants from Daiichi-Sankyo, Inc., Genentech, a member of the Roche Group, Morphosys and TG Therapeutics, Inc.

- 5:00 p.m.** Adjourn






Tuesday, August 10

- 7:00 a.m.** Conference Registration  / Breakfast 
- 7:30 a.m.** Welcome 
James O. Armitage, MD and Julie M. Vose, MD, MBA



SCIENTIFIC SESSIONS

What's Next in Lymphoma

MODERATOR: Julie M. Vose, MD, MBA

- 7:40 a.m.**  What's Next for PET/CT in Lymphoid Malignancies
Sally F. Barrington, MBBS, MSc, FRCP, FRCR, MD
- 8:05 a.m.** What's Next for Pathologic Assessment in Lymphoid Malignancies
Catalina Amador, MD
- 8:30 a.m.** What's Next for Radiotherapy in Lymphoid Malignancies
Charles A. Enke, MD
- 8:55 a.m.**  What's Next for Antibody Drug Conjugates (ADCs) in Lymphoid Malignancies
Brad S. Kahl, MD
- 9:20 a.m.**  What's Next for Bispecific T-cell Engager (BiTE) Antibodies in Lymphoid Malignancies
Christopher R. Flowers, MD, MS, FASCO
- 9:45 a.m.**  What's Next for Non-CD20 Based Monoclonal Antibodies in Lymphoid Malignancies
Nancy L. Bartlett, MD
- 10:10 a.m.** Break 

MODERATOR: Richard I. Fisher, MD

- 10:30 a.m.** BEACOPP: Past, Present and Incorporating Brentuximab Vedotin and Checkpoint Inhibitors in Hodgkin Lymphoma
James O. Armitage, MD
- 10:55 a.m.**  ABVD: Past, Present and Incorporating Brentuximab Vedotin and Checkpoint Inhibitors in Hodgkin Lymphoma
Alison J. Moskowitz, MD
- 11:20 a.m.**  PET Pearls and PET-Falls – the Role of PET in Follicular Lymphoma
Judith Trotman, MBChB, FRACP, FRCPA
- 11:45 a.m.** Novel Imaging Modalities in Multiple Myeloma
Christin A. Tiegs Heiden, MD
- 12:10 p.m.** Novel Combination Therapies in Newly Diagnosed Multiple Myeloma
Nina Shah, MD
- 12:35 p.m.** Novel Strategies in Relapsed and Refractory Multiple Myeloma
Muhamed Baljevic, MD, FACP
- 1:00 p.m.** Adjourn

SATELLITE SYMPOSIUM

- 1:00-3:00 p.m.** Beyond the Guidelines - Investigator Perspectives on the Management of Chronic Lymphocytic Leukemia
Administered by Research To Practice
Supported by Educational Grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd., Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Pharmacyclis LLC, An AbbVie Company and Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC and TG Therapeutics, Inc..

LYMPHOMA JEOPARDY

Semi-Finals

MODERATOR: Matthew A. Lunning, DO, FACP

- 3:00-4:00 p.m.** Semi's #1
TEAM NORTH: Stephen M. Ansell, MD, PhD; Timothy S. Fenske, MD, MS; and Sonali M. Smith, MD
TEAM EAST: Jeremy S. Abramson, MD, MMSc; Matthew S. Davids, MD, MMSc; and Andrew D. Zelenetz, MD, PhD
Semi's #2
TEAM SOUTH: Jonathon B. Cohen, MD, MS; Christopher D'Angelo, MD; and Loretta J. Nastoupil, MD
TEAM WEST: Ranjana H. Advani, MD; Alexey V. Danilov, MD, PhD; and David B. Miklos, MD, PhD

ASK THE EXPERTS

- 4:00-5:00 p.m.** iNHL
MODERATOR: Matthew A. Lunning, DO, FACP
Jonathon B. Cohen, MD, MS; Matthew S. Davids, MD, MMSc; and Loretta J. Nastoupil, MD

SATELLITE SYMPOSIUM

- 5:00-6:30 p.m.** Best Practices for Using Novel Therapies for R/R DLBCL
Administered by Medscape Oncology
Supported by Educational Grants from Karyopharm Therapeutics and Morphosys US Inc.

WELCOME RECEPTION

Croquet Lawn

- 7:00-9:00 p.m.**
Conference participants and registered accompanying guests are invited to join the reception. Name badges required.





Wednesday, August 11

- 7:00 a.m.** Breakfast 

SCIENTIFIC SESSIONS

Moving CAR-T Forward

MODERATOR: Matthew A. Lunning, DO, FACP

- 7:30 a.m.**  Management of CAR-T Toxicities
David G. Maloney, MD, PhD
- 7:55 a.m.** Manipulating the T-cell Before and After Apheresis
Jeremy S. Abramson, MD, MMSc
- 8:20 a.m.**  Manipulating the CAR-T Construct
Renier J. Brentjens, MD, PhD
- 8:45 a.m.** Is There a Best T-cell Phenotype for CAR-T?
David B. Miklos, MD, PhD
- 9:10 a.m.**  CAR-T in China
Peihua (Peggy) Lu, MD
- 9:35 a.m.** CAR-T for Other NHL
Julie M. Vose, MD, MBA
- 10:00 a.m.** Break 

CONFERENCE AGENDA

 All times are displayed in Hawaii Standard Time (HST)

MODERATOR: Julie M. Vose, MD, MBA

10:15 a.m. James O. Armitage Lymphoma Clinical Investigator Award
Loretta J. Nastoupil, MD

11:05 a.m. Oliver Press Memorial Lecture
Historical Development of Hodgkin Therapy at Stanford
Ranjana H. Advani, MD

LYMPHOMA JEOPARDY

11:55 a.m. Finals
Matthew A. Lunning, DO, FACP

12:45 p.m. Adjourn

SATELLITE SYMPOSIUM

1:00-3:00 p.m. Current and Emerging CAR T-Cells and Other Cellular Therapies for the Treatment of Patients with Hematologic Malignancies
Administered by Bio Ascend
Supported by Educational Grants from Bristol-Myers Squibb Company and Legend Biotech

ASK THE EXPERTS

3:00-4:00 p.m. HGBCL
MODERATOR: James O. Armitage, MD
Jeremy S. Abramson, MD, MMSc and Andrew D. Zelenetz, MD, PhD

4:00-5:00 p.m. cHL
MODERATOR: R. Gregory Bociek, MD, MSc, FRCP(C)
Ranjana H. Advani, MD and Craig H. Moskowitz, MD

SATELLITE SYMPOSIUM

5:00-6:00 p.m.  A Team-Based Approach to Optimizing Outcomes for Patients with CLL
Administered by Medscape Oncology
Supported by Educational Grants from AbbVie, Inc. and TG Therapeutics, Inc.

6:00 p.m. Adjourn

Thursday, August 12

7:00 a.m. Breakfast 

SCIENTIFIC SESSIONS

Ongoing Debates in Lymphoma


MODERATOR: Matthew A. Lunning, DO, FACP/ Tara M. Graff, DO, MS

7:30 a.m. Utilization of a BTK Inhibitor in 1st Line CLL/SLL
Alexey V. Danilov, MD, PhD and Susan M. O'Brien, MD

8:00 a.m. Integration of Non-CAR-T Based Immunotherapies in the Management of Non-Hodgkin Lymphoma
Stephen M. Ansell, MD, PhD and Bruce D. Cheson, MD, FACP, FAAS, FASCO

8:30 a.m. Utilization of a Cell Free DNA Assessment in Non-Hodgkin Lymphoma Management
Jeremy S. Abramson, MD, MMSc and Andrew D. Zelenetz, MD, PhD


9:00 a.m.  Management of High Risk Follicular Lymphoma
Carla Casulo, MD


9:30 a.m.  Utilization of Oral Therapies in First Line Indolent Non-Hodgkin Lymphoma Management
Jonathan W. Friedberg, MD, MMSc


10:00 a.m. Break 

MODERATORS: Keely M. Hack, MD/James O. Armitage, MD

10:15 a.m. Utilization of Central Nervous System Prophylaxis in High Grade B-cell Lymphomas
Sonali M. Smith, MD

10:45 a.m.  Utilization of X Plus R-CHOP in High Grade B-cell Lymphomas
Jason R. Westin, MD, MS, FACP

11:15 a.m.  Utilization of Radiotherapy in Hodgkin Lymphoma
Alison J. Moskowitz, MD

11:45 a.m.  Utilization of Routine Imaging During Continuous Oral Therapies
John P. Leonard, MD

12:15 p.m. Utilization of Maintenance Rituximab in Mantle Cell Lymphoma
Timothy S. Fenske, MD, MS

12:45 p.m. Adjourn

SATELLITE SYMPOSIUM

1:00-3:00 p.m. Cases from the Community - Investigators Discuss Emerging Research and Actual Patients with Multiple Myeloma
Administered by Research To Practice
 Supported by Educational Grants from AbbVie Inc., Bristol-Myers Squibb Company, Oncopeptides, and Takeda Oncology

ASK THE EXPERTS

3:00-4:00 p.m. PTCL
 MODERATOR: Julie M. Vose, MD, MBA
 Stephen M. Ansell, MD, PhD and Matthew A. Lunning, DO, FACP

4:00-5:00 p.m. MM
 MODERATOR: Matthew A. Lunning, DO, FACP
 Muhamed Baljevic, MD, FACP and Nina Shah, MD

CONFERENCE DINNER Turtle Pointe

7:00-9:00 p.m.
 Conference participants and registered accompanying guests are invited to join. Name badges required.

Friday, August 13

7:00 a.m. Breakfast 

SCIENTIFIC SESSIONS

Best Management Strategies


MODERATOR: Matthew A. Lunning, DO, FACP

7:30 a.m. Best Management of Relapsed or Refractory Follicular Lymphoma
 Jonathon B. Cohen, MD, MS

7:55 a.m. Best Management of Relapsed or Refractory Marginal Zone Lymphoma
 Pier Luigi Zinzani, MD, PhD

8:20 a.m. Best Management of Relapsed or Refractory HGBCL Post CAR-T Cell Therapy
 Grzegorz S. Nowakowski, MD

8:45 a.m. Best Management of TP53 Mutated Mantle Cell Lymphoma
 Luhua (Michael) Wang, MD

9:10 a.m.  Best Management of CD30+ PTCL Post Exposure to Brentuximab Vedotin
 Kerry J. Savage, MD, MSc, FRCPC

9:35 a.m. Best Management of Hodgkin Lymphoma Post Exposure to Brentuximab Vedotin and Checkpoint Inhibitor
 Craig H. Moskowitz, MD

10:00 a.m. Break 

10:15 a.m. Best Management of Relapsed and Refractory CLL/SLL Post BTK and BCL-2 Exposure
 Alexey V. Danilov, MD, PhD

10:40 a.m.  Best Management of Advanced Stage Mycosis Fungoides and Sezary Syndrome
 Steven M. Horwitz, MD

11:05 a.m. Best Management of Cutaneous B-cell Lymphoma
 R. Gregory Bociek, MD, MSc, FRCPC(C)

11:30 a.m. Best Management of HIV Associated High Grade B-cell Lymphomas
 Jeremy S. Abramson, MD, MMSc

11:55 a.m. Take Home Messages from 2021 Pan Pacific Lymphoma Conference
 Matthew A. Lunning, DO, FACP

12:20 p.m. Adjourn

CONFERENCE FACULTY

Jeremy S. Abramson, MD, MMSc

Director, Center for Lymphoma, Massachusetts General Hospital; Associate Professor of Medicine, Harvard Medical School, Boston, MA

Ranjana H. Advani, MD

Saul A. Rosenberg Professor of Lymphoma, Department of Medicine/Oncology, Stanford Cancer Institute, Stanford University Medical Center, Stanford, CA

Catalina Amador, MD

Associate Professor; Section Medical Director, Bone Marrow Laboratory, Hematopathology Laboratory, Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE

Stephen M. Ansell, MD, PhD

Chair, Mayo Clinic Lymphoma Group; Professor of Medicine, Mayo Clinic, Rochester, MN

James O. Armitage, MD★

Joe Shapiro Professor of Medicine, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Muhamed Baljevic, MD, FACP

Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Sally F. Barrington, MBBS, MSc, FRCP, FRCR, MD

Professor of PET Imaging and NIHR Research Professor, KCL and Guy's and St Thomas' PET Centre, School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom

Nancy L. Bartlett, MD

Professor of Medicine, Koman Chair in Medical Oncology, Washington University School of Medicine, St. Louis, MO

R. Gregory Bociek, MD, MSc, FRCP(C)

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Renier J. Brentjens, MD, PhD

Director, Cellular Therapeutics; Associate Chair, Junior Faculty Development, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Carla Casulo, MD

Associate Professor, James P. Wilmot Cancer Center, Department of Hematology/Oncology, University of Rochester Medical Center, Rochester, NY

Bruce D. Cheson, MD, FACP, FAAAS, FASCO

Scientific Advisor to the Lymphoma Research Foundation and with Johns Hopkins Medicine, Bethesda, MD

Jonathon B. Cohen, MD, MS

Associate Professor, Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA

Christopher D'Angelo, MD

Assistant Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Alexey V. Danilov, MD, PhD

Professor, Department of Hematology & Hematopoietic Cell Transplantation; Associate Director, Toni Stephenson Lymphoma Center, City of Hope Comprehensive Cancer Center, Duarte, CA

Matthew S. Davids, MD, MMSc

Associate Professor of Medicine, Harvard Medical School; Director of Clinical Research, Division of Lymphoma, Dana-Farber Cancer Institute, Boston, MA

Charles A. Enke, MD

Professor and Chair, Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE

Timothy S. Fenske, MD, MS

Professor, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

Richard I. Fisher, MD

President and CEO, The Robert C. Young MD Chair in Cancer Research, Fox Chase Cancer Center, Philadelphia, PA

Christopher R. Flowers, MD, MS, FASCO

Professor and Chair, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Theresa Franco, MSN, RN

Vice President, Cancer Center Clinical Operations & Radiology, Fred & Pamela Buffett Cancer Center, Nebraska Medicine, Omaha, NE

Jonathan W. Friedberg, MD, MMSc

Director, James P. Wilmot Cancer Institute; Samuel Durand Professor of Medicine, University of Rochester Medical Center, Rochester, NY

Tara M. Graff, DO, MS

Medical Oncology and Hematology Associates of Iowa, Des Moines, IA

Krishna Gundabolu, MBBS, FACP

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Keely M. Hack, MD

General Hematologist and Medical Oncologist, Sanford Cancer Center, Sioux Falls, SD

Steven M. Horwitz, MD

Associate Attending, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Brad S. Kahl, MD

Professor of Medicine; Director, Lymphoma Program, Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO

David S. Kroll, MD

Associate Vice Chair for Program Development and Innovation, Department of Psychiatry, Brigham Health, Boston, MA

John P. Leonard, MD

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology; Associate Dean for Clinical Research, Executive Vice Chairman, Weill Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY



Peihua (Peggy) Lu, MD

Medical Executive President of Lu Daopei Hospital; Director of Lymphoma and Multiple Myeloma Center; Director of Hematology and Oncology Department; Lu Daopei Hospital, Beijing, China

Matthew A. Lunning, DO, FACP★

Associate Professor, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

David G. Maloney, MD, PhD

Member, Clinical Research Division, Fred Hutchinson Cancer Research Center; Professor of Medicine, Division of Oncology, University of Washington, Seattle, WA

Jared E. Matya, PharmD, BCOP

Focused Population Pharmacist, Blood and Marrow Transplant, Nebraska Medicine, Omaha, NE

David B. Miklos, MD, PhD

Associate Professor of Medicine, Blood and Marrow Transplantation, Stanford University Medical Center, Stanford, CA

Alison J. Moskowitz, MD

Medical Oncologist; Clinical Director, Lymphoma Inpatient Unit, Memorial Sloan Kettering Cancer Center, New York, NY

Craig H. Moskowitz, MD

Physician in Chief, Cancer Service Line, Sylvester Comprehensive Cancer Center; Professor of Medicine, Miller School of Medicine, University of Miami Health System, Miami, FL

Loretta J. Nastoupil, MD

Lead, Early Phase Drug Development, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Grzegorz S. Nowakowski, MD

Associate Professor, Department of Hematology and Oncology, Mayo Clinic, Rochester, MN

Susan M. O'Brien, MD

Professor of Medicine; Associate Director for Clinical Science, Chao Family Comprehensive Cancer Center; Medical Director, Sue and Ralph Stern Center for Cancer Clinical Trials and Research, University of California/Irvine, Orange, CA

Robbe L. Peetz, MBA, PA-C★

Advanced Practice Provider, Manager Cancer Services, Nebraska Medicine, Omaha, NE

Tawny J. Roeder, RN, BSN, BMTCN★

Case Manager, Blood and Marrow Transplantation, Division of Oncology and Hematology, Department of Internal Medicine, Nebraska Medicine, Omaha, NE

Kerry J. Savage, MD, MSc, FRCPC

Professor of Medicine, University of British Columbia; Medical Oncologist, BC Cancer, Vancouver, British Columbia, Canada

Nina Shah, MD

Associate Professor, Department of Medicine, Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA

Sonali M. Smith, MD

Elwood V. Jensen Professor of Medicine; Interim Chief, Section of Hematology/ Oncology; Director, Lymphoma Program, The University of Chicago, Chicago, IL

Christin A. Tiegs Heiden, MD

Assistant Professor, Department of Radiology, Mayo Clinic, Rochester, MN

Meg Trehwhitt, APN-BC, AOCNP

Hematology-Oncology Nurse Practitioner, Nebraska Medicine, Omaha, NE

Judith Trotman, MBChB, FRACP, FRCPA

Clinical Professor, University of Sydney; Head of Department, Haematology, Concord Repatriation General Hospital, Concord, Australia

Julie M. Vose, MD, MBA★

Neumann M. and Mildred E. Harris Professor and Chief, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE

Luhua (Michael) Wang, MD

Professor, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Jason R. Westin, MD, MS, FACP

Associate Professor; Section Chief, Aggressive Lymphoma; Director, Lymphoma Clinical Research Program, Division of Cancer Medicine, Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

Andrew D. Zelenetz, MD, PhD

Medical Director, Quality Informatics; Attending Physician, Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center; Professor of Medicine, Weill Cornell Medicine, New York, NY

Pier Luigi Zinzani, MD, PhD

Professor of Hematology, Institute of Hematology and Medical Oncology "L. e A. Seràgnoli," University of Bologna, Bologna, Italy

E-POSTERS

Pirtobrutinib (LOXO-305), A Next Generation Highly Selective Non-Covalent BTK Inhibitor in Previously Treated MCL and Other NHL: Phase 1/2 Bruin Study Results

Alvaro J. Alencar¹, Nirav N. Shah², James N. Gerson³, Manish R. Patel⁴, Bitu Fakhri⁵, Wojciech Jurczak⁶, Xuan N. Tan⁷, Katharine L. Lewis⁷, Timothy S. Fenske², Catherine C. Coombs⁸, Ian W. Flinn⁹, David J. Lewis¹⁰, Steven Le Gouill¹¹, M. Lia Palomba¹², Jennifer A. Woyach¹³, John M. Pagel¹⁴, Nicole Lamanna¹⁵, Jonathon B. Cohen¹⁶, Minal A. Barve¹⁷, Paolo Ghia¹⁸, Toby A. Eyre¹⁹, Ming Yin²⁰, Binoj Nair²⁰, Donald E. Tsai²⁰, Nora C. Ku²⁰, Anthony R. Mato¹², Chan Y. Cheah⁷, Michael L. Wang²¹, ¹Sylvester Comprehensive Cancer Center, Miami, USA; ²Medical College of Wisconsin, Milwaukee, USA; ³University of Pennsylvania, Philadelphia, USA; ⁴Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, USA; ⁵University of California San Francisco, San Francisco, USA; ⁶Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland; ⁷Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia; ⁸University of North Carolina at Chapel Hill, Chapel Hill, USA; ⁹Sarah Cannon Research Institute, Nashville, USA; ¹⁰University Hospitals Plymouth NHS, Plymouth UK; ¹¹Service d'hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France; ¹²Memorial Sloan Kettering Cancer Center, New York, NY, USA; ¹³The Ohio State University Comprehensive Cancer Center, Columbus, USA; ¹⁴Swedish Cancer Institute, Seattle, USA; ¹⁵Herbert Irving Comprehensive Cancer Center, Columbia University, New York, USA; ¹⁶Winship Cancer Institute, Emory University, Atlanta, GA, USA; ¹⁷Mary Crowley Cancer Research, Dallas, USA; ¹⁸Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; ¹⁹Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, UK; ²⁰Loxo Oncology, Inc, a wholly owned subsidiary of Eli Lilly and Co., Stamford, USA; ²¹MD Anderson Cancer Center, Houston, USA

Lymphoma Diagnosis Directly from Hematoxylin and Eosin Histopathology Slides

Areej Alsaafin¹, Morteza Babaie¹, Zhe Wang¹, Mahjabin Sajadi¹, Soma Sikdar², Adrian Batten², H.R. Tizhoosh¹, ¹Kimia Lab, University of Waterloo, Waterloo, Ontario, Canada; ²Department of Pathology, Grand River Hospital, Kitchener, Ontario, Canada

Venetoclax-Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia: 4-Year Follow-Up Analysis of the Randomized CLL14 Study

Othman Al-Sawaf^{1,2}, Can Zhang¹, Sandra Robrecht¹, Maneesh Tandon³, Anesh Panchal³, Anna-Maria Fink¹, Eugen Tausch⁴, Matthias Ritgen⁵, Karl-Anton Kreuzer¹, Su Young Kim⁶, Clemens-Martin Wendtner⁷, Barbara Eichhorst¹, Stephan Stilgenbauer⁴, Yanwen Jiang⁸, Michael Hallek¹, Kirsten Fischer¹, ¹Department I of Internal Medicine and Center of Integrated Oncology Aachen Cologne Bonn Duesseldorf, University Hospital of Cologne, 50937 Cologne, Germany, +4922147888220, othman.al-sawaf@uk-koeln.de; ²The Francis Crick Institute, London, United Kingdom; ³Roche Products Ltd, Welwyn Garden City, United Kingdom; ⁴Department of Internal Medicine III, Ulm University, Ulm, Germany; ⁵Department II of Internal Medicine, University of Schleswig-Holstein, Kiel, Germany; ⁶AbbVie Inc, Chicago, Illinois, United States; ⁷Department of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, Klinikum Schwabing, Munich, Germany; ⁸Genentech, San Francisco, California, USA

PAK4 and NAMPT as Novel Therapeutic Targets in Diffused Large B-cell Lymphoma, Follicular Small Cleaved Lymphoma and Mantle Cell Lymphoma

Mahmoud Chaker¹, Amro Aboukameel¹, Irfana Muqbil¹, Mariam Iqbal¹, William Senapedis², Erkan Baloglu², Erlene Seymour¹, Radhakrishnan Ramchandren¹, Jeffrey Zonder¹ and Asfar S. Azmi¹, ¹Department of Oncology, Wayne State University; ²Karyopharm Therapeutics Inc, Newton Massachusetts

Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial In Progress)

Nancy L. Bartlett¹, Christopher A. Yaseenchak², Khaleel Ashraf³, William Harwin⁴, Robert Sims⁵, Grzegorz Nowakowski⁶, ¹Division of Oncology, Washington University School of Medicine, St. Louis, MO, USA; ²Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR, USA; ³Hematology and Oncology Associates of Alabama, Birmingham, AL, USA; ⁴Sarah Cannon Research Institute, Fort Meyers, FL, USA; ⁵Seagen Inc., Bothell, WA, USA; ⁶Division of Hematology, Mayo Clinic, Rochester, MN, USA

Barriers to Enrollment in Clinical Trials for Aggressive B-Cell Lymphoma Progressing after CAR T-Cell Therapy

Evandro Dantas Bezerra¹, Matthew J. Maurer², Arushi Khurana¹, Yucai Wang¹, Matthew Hathcock¹, Radhika Bansal¹, Jonas Paludo¹, Jose Caetano Villasboas¹, Patrick B. Johnston¹, N. Nora Bennani¹, Stephen M. Ansell¹, Thomas Matthew Habermann¹, Thomas E. Witzig¹, Grzegorz S. Nowakowski¹, Yi Lin¹, ¹Division of Hematology, Mayo Clinic, Rochester, MN, USA; ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA

Early PET Imaging Following CAR-T for Aggressive Lymphoma: Analysis of Metabolic Characteristics and Prognostic Differentiation of Patients Who Do Not Achieve Complete Response at Month 1

William Breen, Matthew Hathcock, Jason Young, Roman Kowalchuk, Radhika Bansal, Arushi Khurana, N. Nora Bennani, Jonas Paludo, Jose Villasboas Bisneto, Yucai Wang, Stephen Ansell, Jennifer Peterson, Patrick Johnston, Scott Lester, and Yi Lin. Mayo Clinic, Rochester, Minnesota

ENCORE — Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

Tyler Phillips¹, Kristina S. Yu², Nicholas Liu², Andy Surinach³, Carlos Flores³, Julie Lisano², Michelle A. Fanale², John M. Burke⁴, ¹University of Michigan Medical School Department of Internal Medicine, Division of Hematology/Oncology, Ann Arbor, MI, USA; ²Seagen, Bothell, WA, USA; ³Genesis Research, Hoboken, NJ, USA; ⁴Rocky Mountain Cancer Centers, Aurora, CO, USA

Reducing the Burden of Oncological Therapy in Children, Adolescents and Young Adults (CAYA) with Mature B-Cell(MBL) and Hodgkin Lymphoma (HL): A Path Forward for Adult Lymphoma

Mitchell S. Cairo, MD,^{1,2,3,4,5} Jessica Hochberg, MD,¹ Qiuhu Shi, PhD,⁶ Matthew Barth, MD,⁸ Jaclyn Basso, RN, MSN, PNP,¹ Allyson Flower, MD,¹ Humayan Islam, MD,³ Perry Gerard, MD,⁷ Liana Klejmont, PharmD,¹ Aliza Gardenswartz, MD,¹ Lauren Harrison, RN, MSN,¹ Erin Morris, RN,¹ Rodney Miles, MD, PhD,⁹ and Stanton Goldman, MD¹⁰, Departments of Pediatrics¹, Medicine², Pathology³, Microbiology & Immunology⁴, Cell Biology & Anatomy⁵, Biostatistics⁶, and Radiology⁷, New York Medical College, Valhalla, NY, USA; Department of Pediatrics⁸, Roswell Park Cancer Institute, Buffalo, NY, USA; Department of Pathology⁹, University of Utah, Salt Lake City, UT, USA; Department of Pediatrics¹⁰, Medical City Dallas, Dallas, TX, USA

Optimizing Patient Outcomes with Consolidative Radiotherapy in the Salvage Management of Hodgkin Lymphoma

Brendan Coutu, MD¹, Elliot Lawrence, MD¹, Robert G. Bociek, MD², James Armitage, MD², and Charles Enke, MD¹, ¹Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, NE; ²Division of Hematology/Oncology, Department of Medicine, University of Nebraska Medical Center, Omaha, NE

Targeting Transcriptional Regulation of Pi3k Signaling Pathway in B-Cell Lymphoma

Sinisa Dovat¹, Chandrika Gowda¹, Yali Ding¹, and Dhimant Desai¹, ¹Pennsylvania State University College of Medicine, Hershey, PA, USA

An Unclassifiable B-Cell Lymphoma in a Tongue Mass of an 86-Year-Old Female

Kaia Erickson, MD and Douglas Lynch, MD, University of South Dakota Sanford Medical Center, Sioux Falls, SD, USA

ENCORE — Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

John M. Burke¹, Nicholas Liu², Kristina S. Yu², Michelle A. Fanale², Andy Surinach³, Carlos Flores³, Julie Lisano², Tycel Phillips⁴, 1. Rocky Mountain Cancer Centers, Aurora, CO, USA; 2. Seagen, Bothell, WA, USA; 3. Genesis Research, Hoboken, NJ, USA; 4. University of Michigan Medical School Department of Internal Medicine, Division of Hematology/Oncology, Ann Arbor, MI, USA

Healthcare Resource Utilization and Costs in Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Using Real-World Data from the United States

Christina Cool, MPH [1], Chaoling Feng, PhD [2], Sally W. Wade, MPH [3], Reina Rau, MPH [1] Kenneth Ching, PhD [1], Liliosa Nyamutswa, MPH [2], Behzad Kharabi, MD [2] Adam Duvall MD, MPH [4], [1] PRECISIONheor, New York, NY USA [2] Kite, A Gilead Company, Santa Monica, CA USA [3] Wade Outcomes Research and Consulting, Salt Lake City, UT USA [4] University of Chicago, Chicago, IL, USA

Brentuximab Vedotin in Combination with Nivolumab, Doxorubicin, and Dacarbazine in Newly Diagnosed Patients with Advanced Stage Hodgkin Lymphoma (SGN35-027, Trial In Progress)

Ian Flinn¹, Judah D. Friedman², Linda Ho³, Hun Ju Lee⁴, ¹Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USA; ²University Hospitals Seidman Cancer Center, Cleveland, OH, USA; ³Seagen Inc., Bothell, WA, USA; ⁴MD Anderson Cancer Center, Houston, TX, USA

Change in Lymphocyte Count as a Predictor of Response to Mogamulizumab in Patients with Mycosis Fungoides or Sézary Syndrome

Francine Foss, MD¹; Takahiro Ito, MSc²; Karen Dwyer, BA²; Fiona Herr, PhD³, ¹Yale University School of Medicine, New Haven, CT, USA; ²Kyowa Kirin, Inc., Princeton, NJ, USA; ³Kyowa Kirin, Inc., Bedminster, NJ, USA

Promising Tolerability and Efficacy Results from Dose-Escalation in an Ongoing Phase IB/II Study of Mosunetuzumab with Polatuzumab Vedotin (Pola) In Patients (PTS) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL)

Elizabeth Budde,¹ Nilanjan Ghosh,² Julio Chavez,³ Izidore S. Lossos,⁴ Amitkumar Mehta,⁵ Kathleen Dorritie,⁶ Manali Kamdar,⁷ Raluca Negricea,⁸ Song Pham,⁹ Maria Hristopoulos,⁹ Ling-Yuh Huw,⁹ Carol O'Hear,⁹ Yasuhiro Oki,⁹ Iris To,⁹ Catherine Diefenbach¹⁰, ¹City of Hope National Medical Center, Duarte, CA, USA; ²Hematologic Oncology and Blood Disorders, Levine Cancer Institute/Atrium Health, Charlotte, NC, USA; ³Moffitt Cancer Center, Tampa, FL, USA; ⁴Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, FL, USA; ⁵O'Neal Comprehensive Cancer Center at The University of Alabama at Birmingham, Birmingham, AL, USA; ⁶UPMC Hillman Cancer Center, Pittsburgh, PA, USA; ⁷University of Colorado Cancer Center, Aurora, CO, USA; ⁸F. Hoffmann-La Roche Ltd, Basel, Switzerland; ⁹Genentech, Inc., South San Francisco, CA, USA; ¹⁰Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA

Hypomagnesemia at Time of Autologous Stem Cell Transplantation is Associated with an Increased Risk of Failure in Patients with Diffuse Large B-Cell Lymphoma

Jennifer J. Gile¹ M.D., Camden L. Lopez² M.S., Gordon J. Ruan¹ M.D., Matthew A. Hathcock², Jithma P. Abeykoon¹ M.D., Joy R. Heimgartner³ RDN, Nikola A. Baumann Ph.D., M. Molly McMahon³ M.D., Ivana N. Micallef¹ M.D., Patrick B. Johnston¹ M.D., Ph.D., Jose C. Villasboas Bisneto¹ M.D., Luis F. Porrata¹ M.D., Jonas Paludo¹ M.D., Stephen M. Ansell¹ M.D., Ph.D., William J. Hogan¹ M.B., B.Ch., Thomas E. Witzig¹ M.D., ¹Division of Hematology, Department of Medicine, and ²Department of Biomedical Statistics and Informatics and ³Division of Endocrinology, Department of Medicine, Mayo Clinic Rochester, MN 55905

Overview of 3rd Line Therapies for Follicular Lymphoma in the Modern Era: An Advanced Practice Provider Perspective

Guerrero, M.D. and Mistry, H.E., The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

E-POSTERS

5-Year Update of the Murano Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Following Fixed-Duration Venetoclax-Rituximab Therapy

Rosemary Harrup,^{*1} Arnon P. Kater,^{*2} Thomas J. Kipps,³ James D'Rozario,⁴ Carolyn Owen,⁵ Tadeusz Robak,⁶ Javier de la Serna,⁷ Marco Montillo,⁸ Clemens Mellink,² Mariana Cota Stirner,⁹ Jenny Wu,¹⁰ Yanwen Jiang,¹⁰ Maria Thadani-Mulero,¹¹ Marcus Lefebure,¹¹ Michelle Boyer,¹¹ John F. Seymour,¹² Royal Hobart Hospital, University of Tasmania, Tasmania, Australia; ²Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; ³UCSD Moores Cancer Center, San Diego, CA, USA; ⁴The John Curtin School of Medical Research, Australian National University, Canberra, Australia; ⁵University of Calgary, Calgary, Canada; ⁶Medical University of Lodz, Lodz, Poland; ⁷Hospital Universitario 12 de Octubre, Madrid, Spain; ⁸Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy; ⁹AbbVie, North Chicago, IL, USA; ¹⁰Genentech, Inc. South San Francisco, CA, USA; ¹¹Roche Products Ltd, Welwyn Garden City, UK; ¹²Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Australia
*Co-first authors listed alphabetically

The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin (BV) and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients (PTS) with CD30-Positive Peripheral T-CELL Lymphoma (PTCL)

Steven Horwitz¹, Owen A. O'Connor², Barbara Pro³, Tim Illidge⁴, Swaminathan Iyer⁵, Ranjana Advani⁶, Nancy L. Bartlett⁷, Jacob Haaber Christensen⁸, Franck Morschhauser⁹, Eva Domingo-Domenech¹⁰, Giuseppe Rossi¹¹, Won Seog Kim¹², Tatyana Feldman¹³, Tobias Menne¹⁴, David Belada¹⁵, Árpád Illés¹⁶, Kensei Tobinai¹⁷, Kunihiro Tsukasaki¹⁸, Su-Peng Yeh¹⁹, Andrei Shustov²⁰, Andreas Hüttmann²¹, Kerry J. Savage²², Sam Yuen²³, Pier Luigi Zinzani²⁴, Harry Miao²⁵, Veronica Bunn²⁵, Keenan Fenton²⁶, Michelle Fanale²⁶, Markus Puhlmann²⁶, Lorenz Trümper²⁷, ¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²E. Couric Cancer Center, University of Virginia, Charlottesville, VA, USA and TG Therapeutics, New York, NY, USA; ³Northwestern University Feinberg School of Medicine, Chicago, IL, USA; ⁴Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, NIHR Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust, Manchester, UK; ⁵MD Anderson Cancer Center/University of Texas, Houston, TX, USA; ⁶Stanford Cancer Center, Blood and Marrow Transplant Program, Stanford, CA, USA; ⁷Washington University School of Medicine, St. Louis, MI, USA; ⁸Odense University Hospital, Odense, Denmark; ⁹CHRU de Lille, Lille cedex, Nord-Pas-de-Calais, France; ¹⁰Institut Catala D'oncologia, L'Hospitalet de Llobregat, Barcelona, Spain; ¹¹Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Italy; ¹²Samsung Medical Center, Seoul, Republic of Korea; ¹³Hackensack University Medical Center, Hackensack, NJ, USA; ¹⁴Freeman Hospital, Newcastle upon Tyne, England; ¹⁵4th Department of Internal Medicine – Hematology, University Hospital Hradec Králové, Czech Republic and Charles University in Prague, Faculty of Medicine in Hradec Králové, Czech Republic; ¹⁶Debreceni Egyetem, Debrecen, Hajdu-Bihar, Hungary; ¹⁷National Cancer Center Hospital, Tokyo, Japan; ¹⁸Saitama Medical University International Medical Center, Saitama, Japan; ¹⁹China Medical University Hospital, Taichung, Taiwan; ²⁰University of Washington Medical Center, Seattle, WA, USA; ²¹Universitätsklinikum Essen, Essen, Nordrhein-Westfalen, Germany; ²²Department of Medical Oncology and University of British Columbia, BC Cancer, Vancouver, BC, Canada; ²³Calvary Mater Newcastle Hospital, Australia; ²⁴Institute of Hematology "Seràgnoli" University of Bologna, Bologna, Italy; ²⁵Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceuticals Limited; ²⁶Seagen Inc., Bothell, WA, USA; ²⁷Universitätsmedizin Göttingen, Göttingen, Germany

Burkitt Lymphoma: Unexpected Cause of Abdominal Fullness in Pregnancy

Tien-Chan Hsieh, MD^{1,2,3}, Russell Lewis, Jr, MD¹, Sean X. Gu, MD/PhD⁴, Zenggang Pan, MD/PhD⁴, Stephanie Halene, MD/PhD¹, ¹Department of Internal Medicine and Yale Comprehensive Cancer Center, Yale University School of Medicine, 333 Cedar St, New Haven, CT 06510; ²Department of Medicine, Danbury Hospital, Danbury, CT, USA; ³Department of Medicine, University of Vermont, Burlington, VT, USA; ⁴Department of Pathology, Yale University School of Medicine, 310 Cedar Street New Haven, Connecticut, 06510

Frontline Brentuximab Vedotin and CHP (A+CHP) In Patients with Peripheral T-Cell Lymphoma with <10% CD30 Expression (SGN35032, Trial In Progress)

Deepa Jagadeesh¹, Scott Knowles², Steven M. Horwitz³, ¹Cleveland Clinic Taussig Cancer Institute and Case Comprehensive Cancer Center, Cleveland, OH, USA; ²Seagen Inc. and University of Washington, Bothell and Seattle, WA, USA; ³Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA

Clinical Activity of Loncastuximab Tesirine Plus Ibrutinib in Non-Hodgkin Lymphoma: Updated LOTIS-3 Phase 1 Results

M Janakiram¹, J Depaus², N Wagner-Johnston³, P L Zinzani⁴, T J Phillips⁵, S Ferrari⁶, L J Bryan⁷, V Delwail⁸, S de Guibert⁹, M Tani¹⁰, V Dai¹¹, K Havenith¹², J Boni¹¹, X He¹¹, A Ervin-Haynes¹¹, C Carlo-Stella¹³, ¹Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA; ²Department of Hematology, CHU UCL Namur site Godinne, Yvoir, Belgium; ³Division of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA; ⁴IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli", and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy; ⁵University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA; ⁶Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy; ⁷Department of Medicine, Division of Hematology/Oncology, Georgia Cancer Center at Augusta University, Augusta, GA, USA; ⁸Department of Hematology and Cell Therapy, Centre Hospitalier Universitaire de Poitiers, Poitiers, France; ⁹Department of Clinical Hematology, Centre Hospitalier Universitaire de Rennes Hôpital Pontchaillou, Rennes, France; ¹⁰Unit of Hematology, Santa Maria delle Croci Hospital, Ravenna, Italy; ¹¹Clinical Development, ADC Therapeutics America, Inc., Murray Hill, NJ, USA; ¹²ADC Therapeutics (UK) Ltd, London, UK; ¹³Department of Biomedical Sciences, Humanitas University and IRCCS Humanitas Research Hospital, Milan, Italy

Racial, Ethnic, and Socioeconomic Disparities in Treatment Outcomes in Patients (PTS) with Diffuse Large B-Cell Lymphoma (DLBCL): A US Real-World Study Using a De-Identified Electronic Health Record (EHR)-Derived Database

Yanling Jin,¹ Jia Li,² Yong Mun,² Anthony Masaquel,² Sylvia Hu,² Juliana M. L. Biondo,² Scott Huntington³, ¹F. Hoffmann-La Roche Ltd, Mississauga, ON, Canada; ²Genentech, Inc., South San Francisco, CA, USA; ³Division of Hematology and Oncology, Department of Internal Medicine, Yale University, New Haven, CT, USA

Congratulations to our 2021 PPLC Abstract Travel Stipend Recipients

Brendan Coutu, MD

Kaia Erickson, MD

Maria Guerrero, DNP, APRN, AOCNP

Tien-Chan Hsieh, MD

Aleksei Konstantinovich Koviadin, MD

Haleigh Mistry, PA

Vladimir Otasevic, MD

Justin Taylor, MD

LOTIS 2 Follow-Up Analysis: Updated Results from a Phase 2 Study of Loncastuximab Tesirine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Brad S. Kahl¹, Mehdi Hamadani², Paolo F. Caimi³, Carmelo Carlo-Stella⁴, Weiyun Ai⁵, Juan Pablo Alderuccio⁶, Kirit M. Ardeshtna⁷, Brian Hess⁸, John Radford⁹, Melhem Solh¹⁰, Anastasios Stathis¹¹, Jay Feingold¹², David Ungar¹², Yajuan Qin¹², Shui He¹², Pier Luigi Zinzani¹³, ¹Department of Medicine, Oncology Division, Washington University, St. Louis, MO, USA, ²Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA, ³University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, USA, ⁴Department of Oncology and Hematology, Humanitas Clinical and Research Center – IRCCS, and Humanitas University, Rozzano, Milan, Italy, ⁵Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, CA, USA, ⁶Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA, ⁷Department of Haematology, University College London Hospitals NHS Foundation Trust, London, UK, ⁸Division of Hematology and Medical Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA, ⁹NIHR Clinical Research Facility, Christie NHS Foundation Trust and the University of Manchester, Manchester, UK, ¹⁰Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA, ¹¹Oncology Institute of Southern Switzerland, Bellinzona, Switzerland, ¹²Clinical Development, ADC Therapeutics America, Inc., Murray Hill, NJ, USA, ¹³IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia “Seràgnoli”, and Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy

Glofitamab Step-Up Dosing (SUD): Updated Efficacy Data Show High Complete Response Rates in Heavily Pretreated Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) Patients (PTS)

Carmelo Carlo-Stella,¹ Cyrus Khan,² Martin Hutchings,³ Fritz C. Offner,⁴ Franck Morschhauser,⁵ Emmanuel Bachy,⁶ Michael Crump,⁷ Anna Sureda,⁸ Gloria Iacoboni,⁹ Corinne Haioun,¹⁰ David Perez-Callejo,¹¹ Linda Lundberg,¹¹ James Relf,¹² Emma Clark,¹² David Carlile,¹² Emily Piccione,¹³ Anton Belousov,¹¹ Kathryn Humphrey,¹² Michael J. Dickinson¹⁴, ¹Humanitas University and Humanitas Research Hospital, Milan, Italy; ²Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA; ³Rigshospitalet, Copenhagen, Denmark; ⁴Universitair Ziekenhuis Gent, Ghent, Belgium; ⁵Hôpital Claude Huriez and Centre Hospitalier Régional Universitaire de Lille, Lille, France; ⁶Hospices Civils de Lyon and Université Claude Bernard, Pierre-Bénite, France; ⁷Princess Margaret Hospital, Toronto, ON, Canada; ⁸Institut Català d'Oncologia Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain; ⁹Vall d'Hebron University Hospital, Barcelona, Spain; ¹⁰Hopital Henri Mondor, AP-HP, Créteil, France; ¹¹F. Hoffmann-La Roche Ltd, Basel, Switzerland; ¹²Roche Products Ltd, Welwyn Garden City, United Kingdom; ¹³Genentech, Inc., South San Francisco, CA, USA; ¹⁴Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, VIC, Australia

Upfront High-Dose Chemotherapy with Autologous Stem Cell Transplantation as a Prognostic Factor for IV Stage and High-Intermediate/High IPI Risk Groups of Diffuse Large B-Cell Lymphoma

A.K. Koviadin¹, L.V. Filatova¹, I.S. Zyuzgin¹, A.S. Artemyeva², M.S. Motalkina¹, Yu. A. Chudinovskikh¹, S.A. Volchenkov¹, I.L. Poliatskin², E.V. Cherkasova¹, S.A. Shalae¹, I.V. Ishmatova¹, A.A. Zverkova¹, M.I. Ghanzin¹, D.S. Burda², T.Yu. Semiglazova³, ¹Department of Hematology and Chemotherapy with intensive care unit, ²Department of Pathology, ³Department of Innovative Methods in Therapeutic Oncology and Rehabilitation, NMRC of Oncology named after N.N. Petrov of MoH of Russia, Saint-Petersburg, Russian Federation

E-POSTERS

A Case Report of Rare Primary Colonic Diffuse Large B-Cell Lymphoma

G. Libonate OMS-III¹, K. Sankoorikal OMS-III¹, K. McKay OMS-III¹, S. Alrefai MD^{1,2}, ¹Edward Via College of Osteopathic Medicine – Blacksburg, VA, United States of America; ²Sentara Halifax Regional Hospital, Department of Surgery – South Boston, VA, USA

Encore — Economic Assessment of Diagnostic Revision in Peripheral T-Cell Lymphoma

Nicholas Liu¹, Julie Lisano¹, Kristina S. Yu¹, Deepak Singh¹, David Campbell², Wayne Su², ¹Seagen, Bothell, WA, USA; ²Xcenda, Palm Harbor, FL, USA

Treatment Patterns and Real-World Outcomes in Patients with Large B-Cell Lymphoma Who Received Second-Line Salvage Therapy

Matthew Lunning¹, Min Che², Tao Gu², T. Kim Le², Fei Fei Liu², ¹University of Nebraska Medical Center, Omaha, NE, USA; ²Bristol Myers Squibb, Princeton, NJ, USA

Overview for the Advanced Practice Provider of 3rd Line Therapies for Large B-Cell Lymphoma in the Modern Era

Mistry, H.E and Guerrero, M.D.; The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Multi Targeted Epigenetic Therapies in Lymphoma, A 10 Year Case Study of Successful Treatment of Advanced Mantle Cell Lymphoma

M.Nezami MD, S.Hager DO, acknowledgement: P. Herschberger PhD., California Cancer Associates for Research and Excellence (Fresno, CA), Roswell Park Comprehensive Cancer Center (Buffalo, NY)

Impact of Prior Lines of Therapy on Outcomes Following Non-Transplant Therapy for Relapsed and Refractory DLBCL

Grzegorz S. Nowakowski, Sanjal H. Desai, Carrie A. Thompson, Brian F. Kabat, Rebecca L. King, Yucai Wang, Luis F. Porrata, Umar Farooq, Thomas E. Witzig, James R. Cerhan, Brian K. Link, Steven M. Ansell, Thomas M. Haberman, Matthew J. Maurer, Mayo Clinic, Rochester, MN, USA and University of Iowa, Iowa City, IA, USA

Mosunetuzumab (MOSUN) Monotherapy for Elderly/Unfit Patients (PTS) with First-Line Diffuse Large B-Cell Lymphoma (DLBCL) Continues to Show Promising Safety and Efficacy with Durable Complete Responses

Adam Olszewski¹, Abraham Avigdor^{2,3}, Sunil Babu⁴, Itai Levi⁵, Herbert Eradat⁶, Uri Abadi^{3,7}, Houston Holmes⁸, Matthew McKinney⁹, Dariusz Woszczyk¹⁰, Krzysztof Giannopoulos¹¹, Wojciech Jurczak¹², Ron McCord¹³, Yuying Xie¹⁴, Kati Sarouei¹³, Naseer Qayum¹⁵, Carol O'Hear¹³, Gila Sellam¹⁶, Netanel Horowitz¹⁷, ¹Brown University, Providence, RI, USA; ²Sheba Medical Center, Ramat Gan, Israel; ³Tel Aviv University, Tel Aviv, Israel; ⁴Fort Wayne Medical Oncology and Hematology, Fort Wayne, IN, USA; ⁵Soroka University Medical Centre, Be'er-Sheva, Israel; ⁶University of California, Los Angeles, CA, USA; ⁷Meir Medical Center, Kfar Saba, Israel; ⁸Texas Oncology, Dallas, TX, USA; ⁹Duke Cancer Institute, Durham,

NC, USA; ¹⁰University of Opole, Provincial Hospital, Opole, Poland; ¹¹Medical University of Lublin, Lublin, Poland; ¹²Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland; ¹³Genentech, Inc., South San Francisco, CA, USA; ¹⁴F. Hoffmann-La Roche Ltd, Mississauga, Canada; ¹⁵Roche Products Ltd, Welwyn Garden City, United Kingdom; ¹⁶F. Hoffmann-La Roche Ltd, Basel, Switzerland; ¹⁷Ramban Healthcare Campus, Hifa, Israel

THROLY Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication

Vladimir Otasevic¹, Darko Antic^{1,2}, Sven Borchmann³, Horst Müller³, Andreas Engert³, Vojin Vukovic¹, Kristina Tomic¹, Biljana Mihaljevic^{1,2}, Jawed Fareed⁴, ¹Lymphoma Center, Clinic for Hematology, University Clinical Center of Serbia, Belgrade, Serbia; ²Faculty of Medicine, University of Belgrade, Serbia, ³Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf and German Hodgkin Study Group (GHSg), University of Cologne, Cologne, Germany; ⁴Loyola University Medical Center, Maywood, IL, USA

A Population-Based Simulation Model to Estimate Long-Term Progression-Free Survival and Stem Cell Transplantation for Stage III/IV Classical Hodgkin Lymphoma Based on 5-Year Update of the ECHELON-1 Trial: A US Perspective

Tyler Phillips¹, Kristen Migliaccio-Walle², Kristina S. Yu³, Brian Bloudek², Nicholas Liu³, Michelle Fanale³, John M. Burke⁴, ¹Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; ²Curta Inc., Seattle, WA, USA; ³Seagen Inc., Bothell, WA, USA; ⁴US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO, USA

Outcomes for Recurrent Mantle Cell Lymphoma Post-BTK Inhibitor Therapy in Japan; An Administrative Database Study

Shinya Rai¹, Yoshinori Tanizawa², Zhihong Cai², Masaomi Tajimi², Hiroya Asou², Yu-Jing Huang³, Kaisa Taipale⁴, Lee Bowman³, ¹Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka-sayama, Japan; ²Eli Lilly Japan K.K., Kobe, Japan; ³Eli Lilly and Company, Indianapolis, USA; ⁴Oy Eli Lilly Finland AB, Helsinki, Finland

Transformation of Follicular Lymphoma Into Primary Mediastinal B Cell Lymphoma-Like Large B Cell Lymphoma

Lisa Rimsza¹, Sarah Gibson¹, Colleen Ramsower¹, Tameson Yip¹, Allison Rosenthal², Ryan Robetorye¹, Karen Rech³, James R. Cook⁴, Gerben Duns⁵, Christian Steidl⁵, ¹Dept. of Laboratory Medicine and Pathology, Mayo Clinic, Arizona; ²Dept. of Internal Medicine, Mayo Clinic Arizona; ³Dept. of Laboratory Medicine and Pathology, Mayo Clinic Rochester; ⁴Department of Clinical Pathology, Cleveland Clinic, Ohio; ⁵Dept. of Lymphoid Malignancies, British Columbia Cancer Agency, Vancouver, CA

Distinguishing Between Primary Mediastinal Large B-Cell Lymphoma and Diffuse Large B-Cell Lymphoma Using the LYMPH3CX Assay in a Clinical Molecular Diagnostics Laboratory

Ryan S. Robetorye, MD, PhD, Colleen A. Ramsower, and Lisa M. Rimsza, MD, Molecular Diagnostics - Arizona Lab (MDAZL), Department of Laboratory Medicine and Pathology, Mayo Clinic in Arizona, Scottsdale, AZ, USA

A Phase 2 Study of Retreatment with Brentuximab Vedotin in Patients with CHL, SALCL, or Other CD30 Expressing PTCL (SGN35-28, Trial In Progress)

Jose D Sandoval-Sus¹, Scott Knowles², Julie Lisano², Jingmin Liu², Sairah Ahmed³, ¹Department of Malignant Hematology & Cellular Therapy, H Lee Moffitt Cancer Center at Memorial Cancer Institute, Pembroke Pines, FL, US; ²Seagen Inc. Bothell, WA, US; ³MD Anderson Cancer Center, Houston, TX, USA

Preliminary Results of the Phase 2 Study of Zanubrutinib in Patients with Previously Treated B-Cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib

Mazyar Shadman, MD, MPH¹, Jeff P. Sharman, MD², Moshe Y. Levy, MD³, Ryan Porter, MD⁴, Syed F. Zafar, MD⁵, John M. Burke, MD⁶, Arvind Chaudhry, MD, PhD⁷, Benjamin Freeman, MD⁸, Jamal Misleh, MD⁹, Habte A. Yimer, MD¹⁰, Jennifer L. Cultrera, MD¹¹, Troy H. Guthrie, MD¹², Edwin Kingsley, MD¹³, Subramanya S. Rao, MD¹⁴, Dih-Yih Chen, MD¹⁵, Xiaoping Zhang, MD¹⁵, Adam Idoine, PhD¹⁵, Aileen Cohen, MD, PhD¹⁵, Kunthel By, PhD¹⁵, Jane Huang, MD¹⁵, Ian Flinn, MD, PhD¹⁵, ¹Fred Hutchinson Cancer Research Center, University of Washington, Clinical Research Division, PO Box 19024, 1100 Fairview Ave N, Seattle, WA, 98109 USA; ²Willamette Valley Cancer Institute and Research Center, Eugene, OR, USA; ³Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA; ⁴SSM Health Dean Medical Group, Madison, WI, USA; ⁵Florida Cancer Specialists & Research Institute, Fort Myers, FL, USA; ⁶Rocky Mountain Cancer Centers, Aurora, CO, USA; ⁷Summit Cancer Centers, Spokane, WA, USA; ⁸Summit Medical Group, Florham Park, NJ, USA; ⁹Medical Oncology Hematology Consultants PA, Newark, DE, USA; ¹⁰Texas Oncology-Tyler, Tyler, TX, USA; ¹¹Florida Cancer Specialists & Research Institute, Leesburg, FL, USA; ¹²GenesisCare, Jacksonville, FL, USA; ¹³Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA; ¹⁴Alpha Med Physicians Group, Tinley Park, IL, USA; ¹⁵BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, USA; ¹⁶Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN, USA

Updated Experience from Mosunetuzumab in Multiply Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial

Sarit Assouline,¹ Won Seog Kim,² Laurie H. Sehn,³ Stephen J. Schuster,⁴ Chan Yoon Cheah,⁵ Loretta J. Nastoupil,⁶ Mazyar Shadman,⁷ Sung-Soo Yoon,⁸ Matthew J. Matasar,⁹ Catherine Diefenbach,¹⁰ Gareth P. Gregory,¹¹ Nancy L. Bartlett,¹² Michael C. Wei,¹³ Michelle Y. Doral,¹³ Shen Yin,¹³ Raluca Negricea,¹⁴ Chi-Chung Li,¹³ Elicia Penuel,¹³ Huang Huang,¹⁴ L. Elizabeth Budde¹⁵, ¹Jewish General Hospital, Montreal, QC, Canada; ²Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, Republic of Korea; ³BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada; ⁴Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; ⁵Linear Clinical Research and Sir Charles Gairdner Hospital, Nedlands, WA, Australia; ⁶MD Anderson Cancer Center, Houston, TX, USA; ⁷Fred Hutchinson Cancer Research Center, Seattle, WA, USA; ⁸Seoul National University Hospital, Seoul, Republic of Korea; ⁹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ¹⁰Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA; ¹¹School of Clinical Sciences at Monash Health, Monash University, Clayton, VIC, Australia; ¹²Washington University School of Medicine, St. Louis, MO, USA; ¹³Genentech, Inc., South San Francisco, CA, USA; ¹⁴F. Hoffmann-La Roche Limited, Mississauga, ON, Canada; ¹⁵City of Hope National Medical Center, Duarte, CA, USA

Composite Biomarker Image: Advanced Visualisation for Examination of Hodgkin Lymphoma

Abubakr Shafique¹, Morteza Babaie¹, Adrian Batten², Soma Skdar², and Hamid Tizhoosh¹, ¹Kimia Lab, University of Waterloo, Waterloo, ON, Canada, ²Grand River Hospital, Kitchener, ON, Canada

Cost-Effective of Radiotherapy in the PET/CT-ERA for Early-Stage Hodgkin's Lymphoma

Hayeon Kim PhD¹, Adam Richman MD¹, Kenneth J Smith MD MS², Parvez M. Shaikh MD³, Sushil Beriwal MD MBA¹, John A. Vargo MD¹, ¹Department of Radiation Oncology, UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA ²Clinical and Translational Science and Center for Research on Health Care, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA ³Department of Radiation Oncology, West Virginia University, Morgantown, WV, USA

Healthcare Utilization and Costs Associated with First-Line Treatment with Obinutuzumab- and Rituximab-Based Regimens for Follicular Lymphoma

Jamie T. Ta,¹ Tu My To,¹ Cheryl Sud,¹ Sheila Shapouri,¹ Arpamas Seetasith¹, ¹Genentech, Inc., South San Francisco, CA, USA

Phase 2 Trial of Entospletinib (GS-9973), a Selective syk Inhibitor, in Diffuse Large B-Cell Lymphoma (DLBCL)

Jeff Porter Sharman, Andrei Shustov, James Essell, Dipti Patel-Donnelly, Thomas Rado, Jay Yang, Siddhartha Mitra, Esteban Abella, Jing He, Jing Hu, Robert Chen, Sarit Assouline, John Burke, Willamette Valley Cancer Institute and Research Center/US Oncology Research, Springfield, OR; University of Washington Medical Center, Seattle WA; City of Hope, Duarte, CA; Oncology Hematology Care, Cincinnati, OH; Virginia Cancer Specialists/US Oncology Research, Fairfax, VA; Kadlec Clinic, Richland, WA; Karmanos Cancer Institute/Wayne State University, Detroit, MI; Gilead Sciences, Inc, Foster City, CA; Gerald Bronfman Centre/McGill University, Montreal, Canada; Rocky Mountain Cancer Centers/US Oncology Research, Aurora, CO

Umbralisib Improves Tolerability and Associated Cost Burden of Adverse Events Over PI3K Inhibitors in Relapsed/Refractory Follicular Lymphoma Patients: Results from Matching-Adjusted Indirect Comparison

Sushanth Jeyakumar¹, Sanatan Shrey², Jaime Barnes², Nathaniel Smith¹, Yanzhi Hsu² and Hari Miskin², ¹Maple Health Group, LLC, New York, NY, USA, ²TG Therapeutics, New York, NY, USA

ALLO-HSCT after Mogamulizumab Treatment in MF or SS

Mary Jo Lechowicz, MD¹; Christy Smith, DNP, ACNP-BC²; Robert Ristuccia, PhD²; Karen Dwyer, BA³, ¹The Winship Cancer Institute Emory University, Atlanta, GA, USA; ²Kyowa Kirin, Inc., Bedminster, NJ, USA; ³Kyowa Kirin, Inc., Princeton, NJ, USA

E-POSTERS

Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study

David J. Straus,¹ Monika Długosz-Danecka,² Joseph M. Connors,³ Árpád Illés,⁴ Marco Picardi,⁵ Ewa Lech-Maranda,⁶ Tatyana Feldman,⁷ Piotr Smolewski,⁸ Kerry J. Savage,³ Nancy L. Bartlett,⁹ Jan Walewski,¹⁰ Radhakrishnan Ramchandren,¹¹ Pier Luigi Zinzani,¹² Martin Hutchings,¹³ Javier Munoz,¹⁴ Won Seog Kim,¹⁵ Ranjana Advani,¹⁶ Stephen M. Ansell,¹⁷ Anas Younes,¹⁸ Andrea Gallamini,¹⁹ Sergey Alekseev,²⁰ Hun Ju Lee,²¹ Rachael Liu,²² Meredith Little,²² Keenan Fenton,²³ Michelle Fanale,²³ John Radford²⁴, ¹Memorial Sloan Kettering Cancer Center, New York, NY, USA; ²Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland; ³BC Cancer Centre for Lymphoid Cancer, Vancouver, Canada; ⁴University of Debrecen, Debrecen, Hungary; ⁵Federico II University, Naples, Italy; ⁶Institute of Hematology and Transfusion Medicine, Warsaw, Poland; ⁷Hackensack University Medical Center, Hackensack, NJ, USA; ⁸Medical University of Lodz, Poland; ⁹Siteman Cancer Center, St. Louis, MO, USA; ¹⁰Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland; ¹¹The University of Tennessee Graduate School of Medicine, Knoxville, TN, USA; ¹²Seragnoli Institute of Hematology, Bologna University, Bologna, Italy; ¹³Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ¹⁴Banner MD Anderson Cancer Center, Gilbert, AZ, USA; ¹⁵Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; ¹⁶Stanford University, Stanford, CA, USA; ¹⁷Mayo Clinic, Rochester, MN, USA; ¹⁸AstraZeneca US, Wilmington, DE, USA; ¹⁹Antoine-Lacassagne Cancer Centre, Nice, France; ²⁰Petrov Research Institute of Oncology, St Petersburg, Russia; ²¹University of Texas MD Anderson Cancer Center, Houston, TX, USA; ²²Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; ²³Seagen Inc., Bothell, WA, USA; ²⁴University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK

Real-World Treatment Patterns and Outcomes in Patients with Follicular Lymphoma in the United States

Jamie T. Ta,¹ Taha Itani,² Sheila Shapouri,¹ Stella Arndorfer,³ Cristina Julian,¹ Mei Wu,¹ Giovanni d'Ario,⁴ Cheryl Sud¹, ¹Genentech, Inc., South San Francisco, CA, USA; ²Roche Products Ltd, Welwyn Garden City, England; ³Genesis Research, Hoboken, NJ, USA; ⁴F. Hoffmann-La Roche Ltd, Basel, Switzerland

Pirtobrutinib (LOXO-305), A Next Generation, Highly Selective, Non-Covalent BTK Inhibitor in Previously Treated CLL/SLL: Results from the Phase 1/2 BRUIN Study

Justin Taylor¹, John M. Pagel², Catherine C. Coombs³, Nirav N. Shah⁴, Nicole Lamanna⁵, Ewa Lech-Maranda⁶, Toby A. Eyre⁷, Jennifer A. Woyach⁸, William G. Wierda⁹, Chan Y. Cheah¹⁰, Lindsey E. Roeker¹¹, Manish R. Patel¹², Bita Fakhri¹³, Minal A. Barve¹⁴, Constantine S. Tam¹⁵, David J. Lewis¹⁶, James N. Gerson¹⁷, Alvaro Alencar¹, Omar Abdel-Wahab¹¹, Paolo Ghia¹⁸, Stephen J. Schuster¹⁷, Jessica Chen¹⁹, Binoj Nair²⁰, Donald E. Tsai²⁰, Nora C. Ku²⁰, Matthew S. Davids²¹, Jennifer R. Brown²¹, Wojciech Jurczak²², Anthony R. Mato¹¹, ¹University of Miami Miller School of Medicine, Miami, USA; ²Swedish Cancer Institute, Seattle, USA; ³University of North Carolina at Chapel Hill, Chapel Hill, USA; ⁴Medical College of Wisconsin, Milwaukee, USA; ⁵Herbert Irving Comprehensive Cancer Center,

Columbia University, New York, USA; ⁶Institute of Hematology and Transfusion Medicine, Warsaw, Poland; ⁷Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, UK; ⁸The Ohio State University Comprehensive Cancer Center, Columbus, USA; ⁹MD Anderson Cancer Center, Houston, USA; ¹⁰Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia; ¹¹Memorial Sloan Kettering Cancer Center, New York, USA; ¹²Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, USA; ¹³University of California San Francisco, San Francisco, USA; ¹⁴Mary Crowley Cancer Research, Dallas, USA; ¹⁵Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia; ¹⁶Plymouth Hospitals NHS Trust – Derriford Hospital, Plymouth, UK; ¹⁷Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, USA; ¹⁸Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy; ¹⁹Eli Lilly and Company, Indianapolis, IN, USA; ²⁰Loxo Oncology, Inc, a wholly owned subsidiary of Eli Lilly and Co., Stamford, CT, USA; ²¹Dana-Farber Cancer Institute and Harvard Medical School, Boston, USA; ²²Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland

Progression-Free Survival at 24 Months as a Landmark after Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Aung M. Tun,¹ Seth Maliske,² Yucai Wang,³ Matthew J. Maurer,⁴ Ivana N. M. Micallef,³ David James Inwards,³ Luis F. Porrata,³ Allison Claire Rosenthal,⁵ Mohamed Kharfan-Dabaja,⁶ Jacob Orme,³ Brian K. Link,⁷ James Robert Cerhan,⁴ Carrie A. Thompson,³ Thomas Matthew Habermann,³ Thomas E. Witzig,³ Stephen M. Ansell,³ Grzegorz S. Nowakowski,³ Umar Farooq,² Patrick B. Johnston³, ¹The University of Kansas Cancer Center, Westwood, KS, USA; ²University of Iowa, Iowa City, IA, USA; ³Division of Hematology, Mayo Clinic, Rochester, MN, USA; ⁴Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA; ⁵Division of Hematology, Mayo Clinic, Phoenix, AZ, USA; ⁶Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA; ⁷University of Iowa Carver College of Medicine, Iowa City, IA, USA

FRONT-MIND: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Comparing Efficacy and Safety of Tafasitamab + Lenalidomide + R-Chop vs R-CHOP Alone for Newly-Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

Umberto Vitolo,¹ Grzegorz S. Nowakowski,² John M. Burke,³ Christopher P. Fox,⁴ Marek Trnieny,⁵ Annalisa Chiappella,⁶ Sascha Tillmanns,⁷ Andrea Sporchia,⁷ Wolfram Brugger,⁷ Georg Lenz⁸, ¹Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy; ²Division of Hematology, Mayo Clinic, Rochester, MN, USA; ³US Oncology Research and Rocky Mountain Cancer Centers, Aurora, CO, USA; ⁴Department of Clinical Haematology, Nottingham University Hospitals NHS, Nottingham, UK; ⁵1st Department of Medicine, First Medical Faculty, Charles University and General University Hospital, Prague, Czech Republic; ⁶Division of Hematology & Stem Cell Transplant, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milano, Italy; ⁷MorphoSys AG, Planegg, Germany; ⁸Department of Medicine A – Haematology and Oncology, University Hospital Münster, Münster, Germany

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Final Results from a Phase 2 Study

Wang M,¹ Rule S,² Zinzani PL,³ Goy A,⁴ Casasnovas O,⁵ Smith SD,⁶ Damaj G,⁷ Doorduijn JK,⁸ Lamy T,⁹ Morschhauser F,¹⁰ Panizo C,¹¹ Shah B,¹² Davies A,¹³ Eek R,¹⁴ Dupuis J,¹⁵ Jacobsen E,¹⁶ Kater AP,¹⁷ Le Gouill S,¹⁸ Oberic L,¹⁹ Robak T,²⁰ Jain P,¹ Calvo R,²¹ Tao L,²² Długosz-Danecka M,²³ ¹MD Anderson Cancer Center, University of Texas, Houston, TX, USA; ²Plymouth University Medical School, Plymouth, UK; ³Institute of Hematology "Seràgnoli," University of Bologna, Bologna, Italy; ⁴John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA; ⁵CHU Dijon - Hôpital d'Enfants, Dijon, France; ⁶Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA; ⁷Institut d'Hématologie de Basse-Normandie, Caen, France; ⁸Erasmus MC, HOVON Lunenburg Lymphoma Phase I/II Consortium, Rotterdam, Netherlands; ⁹CHU de Rennes, Rennes, France; ¹⁰CHU Lille, ULR 7365 - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées Lille, France; ¹¹Clinica Universidad de Navarra, Pamplona, Spain; ¹²Moffitt Cancer Center, Tampa, FL, USA; ¹³Cancer Research UK Experimental Cancer Medicines Centre, University of Southampton Faculty of Medicine, Southampton, UK; ¹⁴Border Medical Oncology, Albury, Victoria, Australia; ¹⁵Unité Hémopathies Lymphoïdes, AP-HP Hôpital Henri Mondor, Créteil, France; ¹⁶Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; ¹⁷Amsterdam University Medical Center, Amsterdam, on behalf of Hovon, Netherlands; ¹⁸CHU de Nantes—Hotel Dieu, Nantes, France; ¹⁹Institut Universitaire du Cancer—Oncopole Toulouse (IUCT-O), Toulouse, France; ²⁰Medical University of Lodz, Lodz, Poland; ²¹AstraZeneca, Gaithersburg, MD, USA; ²²AstraZeneca, South San Francisco, CA, USA; ²³Maria Skłodowska-Curie National Research Institute of Oncology, Krakow, Poland

In-Class Transition from Parenteral to Oral Proteasome Inhibitor (PI)-Based Therapy: Overview of Current Ixazomib Trials in Multiple Myeloma (MM)

Presley Whidden,¹ Hans C. Lee,² Stephen J. Noga,¹ Ajay K. Nooka,³ Wenming Chen,⁴ Kenshi Suzuki,⁵ Renda H. Ferrari,¹ Ruth Williams,¹ Robert M. Rifkin,⁶ ¹Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited; ²MD Anderson Cancer Center, Houston, TX, USA; ³Emory University Hospital/Winship Cancer Institute, Atlanta, GA, USA; ⁴Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; ⁵Japan Red Cross Medical Center, Shibuya-ku, Tokyo, Japan; ⁶Rocky Mountain Cancer Centers/US Oncology Research, Denver, CO, USA

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Higher Risk (HR) Myelodysplastic Syndrome (MDS): The Phase 3, Randomized, Enhance Study

Guillermo Garcia-Manero, MD¹, Naval G. Daver¹, Jin Xu², Mark Chao², Trisha Chung², Anderson Tan², Vivian Wang², Andrew H. Wei³, Paresh Vyas⁴, and David A. Sallman⁵, ¹The University of Texas MD Anderson Cancer Center, Houston Texas, USA; ²Gilead Sciences, Inc., Foster City, CA, USA; ³The Alfred Hospital and Monash University, Melbourne, Australia; ⁴University of Oxford, Oxford, United Kingdom; ⁵Moffitt Cancer Center, Tampa, FL, USA

ENCORE — Real-World Adherence to National Comprehensive Cancer Network (NCCN) Guidelines Regarding the Usage of PET/CT and Reported Deauville Scores in Advanced Stage Classical Hodgkin Lymphoma: A Community Oncology Practice Perspective

Christopher Yasenchak¹, Nicholas Liu², April Beeks³, Michelle Fanale², Nicholas Robert³, Kristina S. Yu², ¹Willamette Valley Cancer Institute and Research Center/US Oncology Research, Eugene, OR, USA; ²Seagen Inc., Bothell, WA, USA; ³McKesson Life Sciences, The Woodlands, TX, USA

A Population-Based Simulation Model to Estimate Long-Term Progression-Free Survival and Overall Survival Based on 5-Year Update from ECHELON-2 Trial in Patients with Peripheral T-Cell Lymphoma: A US Perspective

Kristina S. Yu¹, Tycel Phillips², Uche Mordi³, Brian Bloudek³, Nicholas Liu¹, Michelle Fanale¹, John M. Burke⁴, ¹Seagen Inc., Bothell, WA, USA; ²Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI, USA; ³Curta Inc., Seattle, WA, USA; ⁴US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO, USA

How Should We Approach Hodgkin Lymphoma (HL) Patients with an Extra Lymphatic Disease (ELD) in the Era of Novel Therapies?

Meltem Kurt Yuksel, Gul Yavuz¹, Cemalettin Ozturk¹, Atilla Uslu¹, Isinsu Kuzu², ¹Ankara University School of Medicine Hematology Department and BMT Unit Ankara Turkey; ²Ankara University School of Medicine Pathology Department Ankara Turkey

Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 PRIMO Trial: Updated Expansion Phase Results

¹Jasmine Zain, ²Pier Luigi Zinzani, ³Jonathan E Brammer, ⁴Monica Mead, ⁵Carla Casulo, ⁶Eric Jacobsen, ⁷Giuseppe Gritti, ⁸Debra Litwak, ⁹David Cohan, ⁹Neha Mehta-Shah, ¹⁰Barbara Pro, ¹¹Steven M. Horwitz, ¹City of Hope, Duarte, California; ²Institute of Hematology University of Bologna, Bologna, Italy; ³The Ohio State University James Comprehensive Cancer Center, Columbus, Ohio; ⁴University of California Los Angeles, California; ⁵University of Rochester, Wilmot Cancer Institute, Rochester, New York; ⁶Dana-Farber Cancer Institute, Boston, Massachusetts; ⁷Hematology and Bone Marrow Transplant Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy; ⁸Secura Bio, Las Vegas, NV; ⁹Washington University School of Medicine in St. Louis, St Louis, Missouri; ¹⁰Northwestern University Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois; ¹¹Memorial Sloan Kettering Cancer Center, New York, New York

CONFERENCE SPONSORS

University of Nebraska Medical Center (Accreditor)

As Nebraska's only public academic health sciences center, the University of Nebraska Medical Center (UNMC) is committed to the education of a 21st century health care work force, to finding cures and treatments for devastating diseases, to providing the best care for patients, and to serving our state and its communities through award-winning outreach. UNMC is also committed to embracing the richness of diversity and is a major economic engine for the state of Nebraska. Led by Chancellor Jeffrey P. Gold, MD, UNMC has six colleges, two institutes, and a graduate studies program, serving nearly 4,000 students in more than two dozen programs. As an academic health science center, UNMC offers patients world-class healthcare, backed by the latest research innovations and practiced by faculty training the next generation of health care providers. With our hospital partner, Nebraska Medicine, UNMC provides services in about 50 specialties, including cancer, neurosciences, heart disease and others. Through this unique combination of academic, scientific, and health care experience, UNMC transforms the discoveries of the laboratory and theory of the classroom into breakthroughs for health.

The mission of the UNMC Continuing Education Programs is to provide specialized and inter-professional educational activities and support innovative research that facilitate individual skills and team-based performance that improves outcomes for patients and communities. Accordingly, UNMC's continuing education efforts aim to enhance the knowledge, skills, attitudes, competence and performance of health care professionals, ultimately improving patient outcomes and community health. This mission statement drives and unifies the continuing education efforts of all colleges and departments at UNMC.

The UNMC Center for Continuing Education (UNMC CCE) is one of this country's oldest accredited providers of continuing education to physicians, started in 1958. By 1967, UNMC CCE, was one of the first seven medical school programs to be ACCME accredited. Throughout its history, UNMC CCE's level and number of activities have grown in certified activities offered, variety of topics, delivery modes, and diversity of audience participants. UNMC CCE offers a broad range of activities from primary care issues to the latest developments in medicine and draws attendees throughout the region, nationally and internationally.

The UNMC College of Nursing Continuing Nursing Education (UNMC CON CNE) has been serving the profession since 1967. Thorough the

creation of engaging continuing nursing education products using state-of-the-art technologies and innovative educational modalities, we strive to improve patient outcomes in Nebraska and around the globe. Our highly developed technical capabilities include instructional design and module development, video streaming, learning activity hosting, custom web development, visual design, dynamic web pages, and data collection, storage, and analysis. The UNMC CON CNE is approved by the California Board of Registered Nursing, and is able to take accredited programs into all 50 states and beyond.

In pursuit of our collective mission, UNMC CCE and UNMC CON CNE work collaboratively to sponsor multi-professional educational activities designed to improve the performance of the health care team and thus patient outcomes. To forward an integrated team-based approach and to facilitate multi-disciplinary and specialized training, UNMC achieved Joint Accreditation provider status effective through November 2024.

UNMC Department of Internal Medicine - Division of Oncology and Hematology

Renowned for the diagnosis, therapy, and research of lymphoma, the UNMC Department of Internal Medicine, Division of Oncology and Hematology has treated patients from all over the world. Patients come for consultation, initial diagnosis, second opinions, standard chemotherapy, participation in clinical research trials, stem cell transplants, and chimeric antigen receptor (CAR) T-cell therapies.

The Division of Oncology and Hematology is comprised of 27 faculty and physicians, with six specializing in lymphoma. The Division is interested in the diagnosis and treatment of all malignancies (cancers). Treatment may include chemotherapy, radiation therapy, immunotherapy, pathway targeted agents, or cellular therapies, including CAR T-cell therapy and bone marrow transplantation.

The Division's physicians specialize in many types of cancers including lymphomas, leukemia, multiple myeloma, urologic, breast, lung, gastric and pancreatic, neuro-oncologic, brain cancer, melanoma, hepatocellular, and other solid tumors.

Nebraska Medicine

Nebraska Medicine is the most esteemed academic health system in the region, consisting of 809 licensed beds at its two hospitals, more than 1,000 physicians, and 40 specialty and primary care clinics in Omaha and surrounding areas.

Nebraska Medicine and UNMC, its research and education partner, share the same mission: to lead the world in transforming lives to create a healthy future for all individuals and communities through premier educational programs, innovative research and extraordinary patient care.

Nebraska Medicine traces its roots back to 1869 with the founding of Omaha's first hospital. In the decades since, it has built an international reputation for breakthroughs in cancer care, organ transplantation and treatment of infectious diseases.

In 2017, Nebraska Medicine earned the Bernard A. Birnbaum, MD Quality Leadership Award from Vizient, Inc. which recognizes it in the top ten quality academic health systems in the United States. For five straight years, Nebraska Medicine has also been named to Becker's Hospital Review's list of 100 Great Hospitals in America.

Fred & Pamela Buffett Cancer Center

The UNMC Fred and Pamela Buffett Cancer Center is the region's only National Cancer Institute (NCI) designated cancer center and is a member of the National Comprehensive Cancer Network (NCCN). The NCCN is an alliance of the nation's 31 leading cancer centers that

develop and institute standards of care for the treatment of cancer and perform outcomes research with the goal of ensuring the delivery of high quality, cost-effective services to cancer patients nationwide.

The Fred & Pamela Buffett Cancer Center has begun changing forever the way cancer is diagnosed and treated. By harnessing the most advanced biomedical and technological tools available, we are increasingly identifying the drivers behind cancer and creating precise therapies that improve outcomes. Through the use of genomics and other new diagnostic tools, we are employing precision medicine to customize therapies and care for each cancer patient.

While all forms of cancer will be treated at the Fred & Pamela Buffett Cancer Center, because of their prevalence in society and the center's potential to have a significant impact in their treatment, the following focus areas have been selected: breast cancer and other women's cancers, head and neck cancers, leukemia and lymphoma, lung cancer, pancreatic and gastrointestinal cancers, and prostate cancer.

The Fred and Pamela Buffett Cancer Center, along with the C.L. Werner Cancer Hospital, aim to provide the side-by-side, rapid development of therapeutics and delivery to patients with cancer.



Photo courtesy of HDR © 2017 Dan Schwalm



University of Nebraska
Medical Center
Nebraska Medicine

SAVE THE DATE

2022 PAN PACIFIC LYMPHOMA CONFERENCE

July 18-22 • Grand Hyatt Kauai

CALL FOR ABSTRACTS

Deadline: Friday, April 22, 2022

FOR MORE INFORMATION www.unmc.edu/panpacificlymphoma